Cover Page  for Protocol  
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN9536 -4578  
Official title of study:  Effect of subcutaneous semaglutide 2.4 mg once -weekly 
compared to placebo  in subjects with obesity and knee 
osteoarthritis  
Document date *: 21 April 2021  
 
*Document date refers to the date on which the document was most recently updated.  
Note: The date in the header from Page [ADDRESS_16852] of contents
Protocol ...............................................................................................................................................
Protocol attachment ...........................................................................................................................CONFIDENTIALDate: Novo Nordisk
Version:
Status:Semaglutide s.c. 2.4 mg once weekly 
Study ID: NN9536-4578 (Knee OA) 
Clinical Study Report
Appendix 9.1.112 January 2024 
1.0
Final
9.1.1 Protocol and protocol amendments
CONFIDENTIAL
Redacted protocol  
Includes redaction of personal identifiable information only.  
. 
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
Status:  Final  
Page:  1 of 90 
Protocol
Protocol title: Effect of subcutaneous semaglutide 2.4 mg once -weekly compared to placebo 
in subjects with obesity and knee osteoarthritis  
Substance name: [CONTACT_18053]: U1111 -[ADDRESS_16853] Number: 2020 -000204 -11 
IND Number: 126,360  
Trial phase:  3b 
In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”.  
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.[ADDRESS_16854] be restricted to relevant 
parties.
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  2 of 90 
 
Protocol amendment summary of changes table  
DOCUMENT HISTORY  
Document  version  Date  Applicable in country( -ies) and/or 
site(s)  
Protocol version 3.0  21 April  2021  CA, CO, DK, FR, NO, RU, SA, ZA, 
ES, SE, US  
Protocol version 2.0  23 Sep 2020  CA, CO, DK, FR, NO, RU, SA, ZA, 
ES, SE, US  
Original protocol version 1.0   24 July 2020  CA, CO, DK, FR, NO, RU, SA, ZA, 
ES, SE, US  
 
Protocol version 3.0 ( 21 April  2021)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Coun cil of the European Union1 for the 
countries participating in the NN9536 -4578 trial.  
Overall rationale for preparing protocol, version 3.0:  
The overall rationale for preparing pr otocol version 3.[ADDRESS_16855] 
been made to registration of concomita nt illness and handling of AEs.  
Section # and name  [CONTACT_18054] 1.[ADDRESS_16856] a more adequate frequency 
of time points for pain assessment to 
capture pain intensity change over 
the entire treatment course.  
Section 1.2 Flowchart  PGI-S will not be assessed at V4 and 
V9. Assessment removed as it will not be 
used in the analysis.  
Section 1.2 Flowchart  PGI-C will not be assessed at V2, 
V4, and V9.  Assessment removed as it will not be 
used in the analysis.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 2 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
Status:  Final  
Page:  3 of 90 
Section 1.2 Flowchart  Addition of a  pain and pain 
medication  diary (training  and 
review) . Daily pain scores are included as 
complementary evidence and permits 
averaging pain intensity by [CONTACT_17973] e ffect of daily variability. 
Recording pain medication enables a 
comparison of change in use of pain 
medication  and groupi[INVESTIGATOR_17936].  
Section 2.[ADDRESS_16857] efficacy 
data in the benefit risk section . 
Section 3.2 Primary, secondary and 
exploratory endpoint(s)  Addition and reorganisation of 
secondary and exploratory 
endpoints . To include endpoints which reflect 
the data obtained in the pain and pain 
medication diary  
Section 5.[ADDRESS_16858] a more adequate pain 
outcome assessment recall period.  
The pain and pain medication diary 
is added to capture changes in pain 
and pain medication.  
Section 8.2 Safety assessments  Inclusion of Cardiovascular Disorder 
and Procedure as part of the 
concomitant illness/medical history 
to be recorded in the eCRF.  To reflect the most updated eCRF.  
Section 8.2  Safety assessments  Inclusion of COVID -19 as part of 
the conc omitant illness/medical 
history to be recorded in the eCRF  When participation in a COVID -[ADDRESS_16859] of AEs that the investigator 
is responsible for detecting, 
documenting, recording and 
following up on.  When participation in a COVID -19 
trial is allowed, the handling of 
COVID -19 related AEs is relevant.  
Section 9.4.2 Primary en dpoint(s)  Addition of WOMAC pain score to 
be taken into account when imputing 
missing data.  To reflect both primary endpoints in 
the imputation.  
Section 10.3.5  Reporting of SAEs  Inclusion of COVID-19 related AEs 
in the Figure 10-1 “Decision tree for 
determining th e event typ e and the 
respectiv e forms to comp lete with 
associated timelines”. When participation in a COVID -19 
trial is allowed, the handling of 
COVID -19 related AEs is relevant  to 
ensure alignment between 
Figure  10-1 and Section 8.3 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 3 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  4 of 90 
 
Section 10. 6 Appendix 6 Amending the appendix: Mitigations 
to ensure subject safety and data 
integrity during COVID -[ADDRESS_16860] in case 
local restrictions due to a COVID -19 
outbreak lead to lock -down of a site.  
Section 10.7 Appendix 7  Deletion of country requirements for 
Russia  The text is included in the 
Agreement with sites.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 4 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  5 of 90 
 
Table of Contents    
 Page  
Protocol amendment summary of changes table  ................................ ................................ ...........................  2 
Table of Contents ................................ ................................ ................................ ................................ ..............  5 
1 Protocol summa ry ................................ ................................ ................................ ................................ ....... 8 
1.1 Synopsis  ................................ ................................ ................................ ................................ ..............  8 
1.2 Flowchart  ................................ ................................ ................................ ................................ ..........  11 
2 Introduction  ................................ ................................ ................................ ................................ ...............  14 
2.1 Trial rationale  ................................ ................................ ................................ ................................ .... 14 
2.2 Background  ................................ ................................ ................................ ................................ ....... 15 
2.2.1  Semaglutide  ................................ ................................ ................................ .......................  15 
2.3 Benefit -risk assessment  ................................ ................................ ................................ .....................  15 
2.3.1  Risk assessment  ................................ ................................ ................................ .................  16 
2.3.2  Benefit assessment  ................................ ................................ ................................ .............  18 
2.3.3  Overall benefit -risk conclusion  ................................ ................................ .........................  19 
3 Objectives and endpoints  ................................ ................................ ................................ ..........................  20 
3.1 Primary, secondary and exploratory objective(s) and estimand(s)  ................................ ...................  20 
3.2 Primary, secondary and exploratory endpoint(s)  ................................ ................................ ..............  22 
3.2.1  Primary endpoints  ................................ ................................ ................................ ..............  22 
3.2.2  Secondary endpoints  ................................ ................................ ................................ ..........  22 
[IP_ADDRESS]  Confirmatory secondary endpoints  ................................ ................................  22 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ .... 22 
3.2.3  Exploratory endpoint(s)  ................................ ................................ ................................ ..... 23 
4 Trial design  ................................ ................................ ................................ ................................ ................  24 
4.1 Overall design  ................................ ................................ ................................ ................................ ... 24 
4.2 Scientific rationale for trial design  ................................ ................................ ................................ .... 24 
4.3 Justification for dose  ................................ ................................ ................................ .........................  25 
4.4 End of trial definition  ................................ ................................ ................................ ........................  25 
5 Trial population  ................................ ................................ ................................ ................................ .........  26 
5.1 Inclusion criteria  ................................ ................................ ................................ ...............................  26 
5.2 Exclusion criteria  ................................ ................................ ................................ ..............................  26 
5.3 Lifestyle considerations  ................................ ................................ ................................ ....................  27 
5.3.1  Caffeine and tobacco  ................................ ................................ ................................ .........  28 
5.4 Screen failures  ................................ ................................ ................................ ................................ ... 28 
5.5 Randomisation criteria  ................................ ................................ ................................ ......................  28 
5.5.1  Randomisation criteria  ................................ ................................ ................................ ....... 28 
6 Treatments  ................................ ................................ ................................ ................................ .................  29 
6.1 Treatments administered  ................................ ................................ ................................ ...................  29 
6.1.1  Medical devices  ................................ ................................ ................................ .................  31 
6.1.2  Diet and Physical Activity counselling  ................................ ................................ .............  31 
[IP_ADDRESS]  Non-investigational medical device(s)  ................................ ...........................  31 
6.2 Preparation/handling/storage/accountability  ................................ ................................ .....................  [ADDRESS_16861]’s home  ................................ ................................ ...... 32 
6.3 Measures to minimise bias: Randomisation and blinding ................................ ................................ . 33 
6.4 Treatment compliance  ................................ ................................ ................................ .......................  33 
6.5 Concomitant medication  ................................ ................................ ................................ ...................  33 
6.5.1  Rescue medication  ................................ ................................ ................................ .............  34 
6.6 Dose modification  ................................ ................................ ................................ .............................  34 
6.7 Treatment after end of trial  ................................ ................................ ................................ ...............  34 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 5 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16862]  discontinuation/withdrawal  ................................ ....... [ADDRESS_16863] discontinuation/withdrawal from the trial  ................................ ................................ ............  [ADDRESS_16864] to follow -up................................ ................................ ................................ ...............................  37 
8 Trial assessments and procedures ................................ ................................ ................................ ............  38 
8.1 Efficacy assessments  ................................ ................................ ................................ .........................  38 
8.1.1  Western Ontario and McMaster Universities Osteoarthritis Index  ................................ ... 38 
8.1.2  Body measurements  ................................ ................................ ................................ ...........  39 
8.1.3  Pain and pain medication diary  ................................ ................................ .........................  39 
8.1.4  Clinical outcome assessments  ................................ ................................ ...........................  40 
8.2 Safety assessments  ................................ ................................ ................................ ............................  41 
8.2.1  Radiographic examinations  ................................ ................................ ...............................  42 
8.2.2  Physical examinations  ................................ ................................ ................................ ....... 42 
8.2.3  Vital signs  ................................ ................................ ................................ ..........................  42 
8.2.4  Clinical s afety laboratory assessments  ................................ ................................ ..............  42 
8.3 Adverse events and serious adverse events  ................................ ................................ .......................  42 
8.3.1  Time period and frequency for collecting AE and SAE information  ................................  43 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ ..................  44 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ .............................  44 
8.3.4  Regulatory reporting requirements for SAEs  ................................ ................................ .... 44 
8.3.5  Pregnancy  ................................ ................................ ................................ ..........................  44 
8.3.6  Cardiovascul ar and death events  ................................ ................................ .......................  44 
8.3.7  Disease -related events and/or disease -related outcomes not qualifying as an AE or 
SAE ................................ ................................ ................................ ................................ .... [ADDRESS_16865]  ................................ ................................ .......................  45 
8.3.9  Technical complaints  ................................ ................................ ................................ .........  45 
8.4 Treatment of overdose  ................................ ................................ ................................ ......................  45 
8.5 Pharmacokinetics  ................................ ................................ ................................ ..............................  45 
8.6 Pharmaco dynamics  ................................ ................................ ................................ ...........................  45 
8.7 Genetics  ................................ ................................ ................................ ................................ ............  45 
8.8 Biomarkers  ................................ ................................ ................................ ................................ ........  45 
8.9 Immunogenicity assessments  ................................ ................................ ................................ ............  46 
8.10 Health economics  ................................ ................................ ................................ ..............................  46 
9 Statistical considerations  ................................ ................................ ................................ ..........................  47 
9.1 Statistical hypotheses  ................................ ................................ ................................ ........................  47 
9.2 Sample size determination  ................................ ................................ ................................ ................  47 
9.3 Populations for analyses  ................................ ................................ ................................ ...................  50 
9.4 Statistical analyses  ................................ ................................ ................................ ............................  51 
9.4.1  General considerations  ................................ ................................ ................................ ...... 51 
9.4.2  Primary endpoint (s) ................................ ................................ ................................ ...........  51 
9.4.3  Secondary endpoints  ................................ ................................ ................................ ..........  52 
[IP_ADDRESS]  Confirmatory secondary endpoints  ................................ ................................  52 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ .... 53 
9.4.4  Exploratory endpoints ................................ ................................ ................................ ........  53 
9.4.5  Other safety analyses  ................................ ................................ ................................ .........  53 
9.4.6  Other analyse(s)  ................................ ................................ ................................ .................  53 
[IP_ADDRESS]  Pharmacokinetic and/or pharmacodynamic modelling  ................................ .. 53 
9.5 Interim analyses  ................................ ................................ ................................ ................................  54 
9.6 Data mon itoring committee  ................................ ................................ ................................ ..............  54 
9.7 Reporting of the main part of the trial  ................................ ................................ ...............................  54 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 6 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
Status:  Final  
Page:  7 of 90 
10 Supporting documentation and operational considerations ................................ ................................ .. 55 
10.1  Appendix 1: Regulatory, ethical, and trial oversight considerations  ................................ ................  55 
10.1.1  Regulatory and ethical considerations  ................................ ................................ ...............  55 
10.1.2  Financial disclosure  ................................ ................................ ................................ ...........  55 
10.1.3  Informed consent process  ................................ ................................ ................................ .. 55 
10.1.4  Information to subjects during trial  ................................ ................................ ...................  56 
10.1.5  Data protection  ................................ ................................ ................................ ..................  56 
10.1.6  Com mittees structure  ................................ ................................ ................................ .........  57 
[IP_ADDRESS]  Novo Nordisk safety committee ................................ ................................ ..... 57 
[IP_ADDRESS]  Trial safety group  ................................ ................................ ...........................  57 
10.1.6 .3 Data monitoring committee ................................ ................................ ............  57 
[IP_ADDRESS]  Event adjudication committee  ................................ ................................ ........  57 
10.1.7  Dissemination of clinical trial data  ................................ ................................ ....................  57 
10.1.8  Data quality assurance  ................................ ................................ ................................ ....... 58 
[IP_ADDRESS] Case report forms  ................................ ................................ ...........................  58 
[IP_ADDRESS]  Monitoring  ................................ ................................ ................................ ..... 58 
[IP_ADDRESS]  Protocol compliance  ................................ ................................ .......................  59 
10.1.9  Source documents . ................................ ................................ ................................ .............  59 
10.1.10  Retention of clinical trial documentation  ................................ ................................ ..........  59 
10.1.11  Trial and site closure ................................ ................................ ................................ ..........  60 
10.1.12  Responsibilities  ................................ ................................ ................................ ..................  60 
10.1.13  Indemnity statement  ................................ ................................ ................................ ..........  61 
10.1.14  Publication policy  ................................ ................................ ................................ ..............  61 
[IP_ADDRESS]  Communication of results  ................................ ................................ ..............  61 
[IP_ADDRESS]  Authorship  ................................ ................................ ................................ ...... 62 
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s) ................................ ................  62 
[IP_ADDRESS]  Investigator access to data and review of results  ................................ ...........  62 
10.2  Appendix 2: Clinical laboratory tests ................................ ................................ ................................  63 
10.3  Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, follow -up, 
and reporting  ................................ ................................ ................................ ................................ ..... 64 
10.3.1  Definition of AE  ................................ ................................ ................................ ................  64 
10.3.2  Definition of an SAE  ................................ ................................ ................................ .........  64 
10.3.3  Description of AEs requiring additional data collection  ................................ ...................  65 
10.3.4  Recording and follow -up of AE and/or SAE  ................................ ................................ ..... 66 
10.3.5  Reporting of SAEs  ................................ ................................ ................................ .............  68 
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy information  ...............................  70 
10.5  Appendix 5: Technical complaints: Definition and procedures for recording, evaluation, 
follow -up and reporting  ................................ ................................ ................................ ....................  73 
10.5.1  Definition of technical complaint  ................................ ................................ ......................  73 
10.5.2  Recording and follow -up of technical complaints  ................................ .............................  73 
10.5.3  Reporting of technical complaints  ................................ ................................ .....................  74 
10.6  Appendix 6: Mitigations to ensure subject safety and data integrity during COVID -19 ..................  75 
10.6.1  Visits  ................................ ................................ ................................ ................................ .. 75 
10.6.2  Assessments  ................................ ................................ ................................ .......................  75 
10.6.3  Minimum assessments following randomisation to be performed during lockdown  ........  76 
10.7  Appendix 7: Country -specific requirements  ................................ ................................ .....................  78 
10.8  Appendix 8: Abbreviations  ................................ ................................ ................................ ...............  82 
10.9 Appendix 9: Protocol amendment history  ................................ ................................ ........................  [ADDRESS_16866] of key staff and relevant departments.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 7 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16867] significant pu blic health challenges worldwide2-8. 
 
Obesity is associated with an increased ri sk of a variety of complications, including osteoarthritis (OA), 
affects physical and mental health and reduces health -related quality of life9-23.  
With the increasing prevalence of obesity, the health issues related to knee OA will intensify with 
huge consequence for society and the individual patient. Due to the pi[INVESTIGATOR_17937], knee OA is associated with significant impairments and limitations to 
basic activities of daily living. The physical disability of knee OA arising from pain and loss of 
functional capacity reduces health -related q uality of life and increases the risk of further morbidity.  
Rationale:  
Weight loss is strongly recommended as a primary management strategy in subjects with knee OA 
and obesity24. However, no specific guidance on how to achieve this is given, and no widely 
available and feasible means to sustain weight loss in subjects with kne e OA and obesity have been 
presented.  
There is a clear association between obesity and knee OA with obesity being a major risk factor for 
the incidence and progression of OA, and negatively influences disease outcomes25, 26. 
In accordance, American College of Rheumatology (ACR) gu idelines strongly recommend weight 
loss in subjects with knee OA and obesity as first line treatment24.  
A significant relationship between weight loss above 10% of body weight and improvement in pain 
and function has been demonstrated in subjects with knee OA and obesity27,28, 29. Pharmacotherapy 
may therefore serve as a valuable adjunct to lifestyle intervention for individuals with knee OA and 
obesity in order to ac hieve a sufficient and sustainable weight loss. In a recent phase 3a study 
(NN9536 -4373) semaglutide s.c. 2.4 mg once -weekly led to a weight loss of 14.9% in subjects with 
overweight and obesity.  
Objectives and endpoints:  
Primary objective  
To confirm super iority of semaglutide s.c. 2.[ADDRESS_16868] to a reduced -calorie diet and increased physical activity in subjects with obesity and knee 
OA in achieving body weight response criteria after 68 weeks from baseline as well as change from 
baseline to week 68 in knee OA -related and general physical function.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 8 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16869] to a reduced -calorie diet and increased physical 
activity, in patients with obesity a nd knee OA, measured by [CONTACT_17974] 68 in 
body weight and knee OA -related pain, regardless of adherence to randomised treatment, regardless 
of initiating other anti -obesity therapi[INVESTIGATOR_014] (weight management drugs or bariatric surgery) or other 
knee OA interventions (joint replacement or steroid injection or opi[INVESTIGATOR_17938] ) and regardless of compliance with washout period for pain medication (the latter only 
relevant in this context for knee OA -related pain) (“treatment po licy” strategy).  
Primary endpoints  
Endpoint title  Time frame  Unit 
Change in body weight  From baseline (week 0) to end of 
treatment (week 68)  % 
Change in WOMAC pain score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
WOMAC; Western Ontario and McMaster Universities Osteoarthritis Index  
Confirmatory secondary endpoints  
Endpoint title  Time frame  Unit 
Achieving body weight reduction 
≥5% (yes/no)  From baseline (week 0) to end of 
treatment (week 68)  Count of subject  
Achieving body weight reduction 
≥10% (yes/no)  From baseline (week 0) to end of 
treatment (week 68)  Count of subject  
Change in WOMAC physical 
function score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 physical 
functioning score  From  baseline (week 0) to end of 
treatment (week 68)  Score points  
Overall design:  
This is a 68 -week, randomised, two -arm, double -blinded, multi -centre clinical trial comparing 
semaglutide s.c. 2.4 mg once -weekly with semaglutide placebo in subjects with moder ate OA of 
one or both knees, pain due to knee OA, and obesity (BMI ≥30.0 kg/m2). 
Eligible subjects fulfilling all randomisation criteria at visit 2 will be randomised in a 2:[ADDRESS_16870] to a reduced -
calorie diet and increased physical activity.  
Key inclusion criteria:  
• Male or female, age above or equal to 18 years at the time of signing informed consent  
• Body Mass Index (BMI) ≥30.0 kg/m2 
• Clinical diagnosis of knee OA ( American College of Rheumatology ( ACR ) criteria) with 
moderate radiographic changes ( Kellgren -Lawrence ( KL) grades 2 or 3 as per central 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 9 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  10 of 90 
 
reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. 
If pain in knees are equal  target knee joint will be in the most dominant leg.  
• Pain due to knee OA  
Key exclusion criteria:  
• Joint replacement in target knee  
• Arthroscopy or injections into target knee within last 3 months prior to enrolment  
• Any other joint disease in the target kn ee 
Number of subjects:  
Approximately [ADDRESS_16871].  
Treatment groups and duration:  
• The total trial duration for the individual subject will be approximately 76 weeks. The trial 
includes a screening period of approximately 2 weeks followed by [CONTACT_17975]. Dose 
escalation of semaglutide/semaglutide placebo will take place every [ADDRESS_16872] 
16 weeks after randomisation. All subjects should aim at reaching the target dose of 
semaglutide 2.4 mg once -weekly. Following randomisation, visits are scheduled every 8th 
week until end -of-treatment (week 68). Follow -up period is 7 weeks after end -of-treatment.     
• The following trial products will be supplied by [CONTACT_3454] A/S for the duration of the 
trial:  
o Semaglutide B 3.0 mg/mL PDS290 and semaglutide placebo, solution for injection, 
3 mL PDS290 pre -filled injector  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 10 90
CONFIDENTIAL
Protocol        Date:  21 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN9536 -4578        Version:  3.0 Page:  11 of 90 
 
1.2 Flowchart  
 Screening  Randomisation  Dose escalation period  Treatment period  End of 
treatment  End of 
trial 
Visit (V)  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 
Timing  of Visit (Weeks)  -1 0 4 8 12 16 20 28 36 44 52 60 68 75 
Visit  Window  (Days)  -7 to 0  ±0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +[ADDRESS_16873] RELATED INFORMATION AND 
ASSESSMENTS                
Informed  Consent  and Demographya (Appendix 
1, Section 10.1) X              
Eligibility  Criteria ( 5.1) X X             
Randomisation  Criteria  & Randomisation ( 5.5)  X             
Concomitant  Medication  X X X X X X X X X X X X X X 
Medical  History/Concomitant  Illness ( 8.2 /6.5) X              
Tobacco  Useb (5.3.1 ) X              
Childbearing  Potential ( Appendix 4, Section 
10.4) X              
Pregnancy  Testc (8.3.5 ) X X  X  X X X X X X X X X 
Knee  Radiography ( 8.2.1 ) X              
EFFICACY                
Body  Measurements ( 8.1.2 )               
     Body  Weight  X X  X   X  X  X  X  
     Height  X              
     Waist  Circumference   X  X   X  X  X  X  
Clinical  Outcome  Assessments                
    Western Ontario and McMaster Universities   
Osteoarthritis Index (WOMAC)  (8.1.1 )  X X X X X X X X X X X X  
NN9536-4578 NN9536 0  |  . -  | 2 VV-TMF-4175464
  Protocol  v 3.0  | 11  of 90
CONFIDENTIAL
Protocol        Date:  21 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN9536 -4578        Version:  3.0 Page:  12 of 90 
 
 Screening  Randomisation  Dose escalation period  Treatment period  End of 
treatment  End of 
trial 
Visit (V)  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 
Timing  of Visit (Weeks)  -1 0 4 8 12 16 20 28 36 44 52 60 68 75 
Visit  Window  (Days)  -7 to 0  ±0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +5  
     Patient Global Impression of Status (PGI -S) 
Pain  X     X    X  X  
    Patient Global Impression of Change (PGI -C) 
Pain       X    X  X  
     Short Form 36 V2.0 acute (SF -36) ( 8.1.4 )  X  X   X  X  X  X  
     PGI-S Physical Function   X     X    X  X  
     PGI-C Physical Function        X    X  X  
     Six-Minute Walking Test ( 8.1.4 )  X           X  
SAFETY                
Adverse  Event ( 8.3)  X X X X X X X X X X X X X 
Technical  Complaint ( 8.3.9 )   X X X X X X X X X X X  
Vital  Signs ( 8.2.3 )               
     Systolic  Blood  Pressure  X X X  X  X  X  X  X X 
     Diastolic  Blood  Pressure  X X X  X  X  X  X  X X 
     Pulse  X X X  X  X  X  X  X X 
Physical  Examination ( 8.2.2 ) X            X  
Laboratory Assessments ( Appendix 2, Section 
10.2)               
    Hemoglobin A1c (HbA1 c) X              
TRIAL MATERIAL                
     IWRS  Session  X X  X  X X X X X X X X  
Administration  of Trial  Product ( 6.1)               
NN9536-4578 NN9536 0  |  . -  | 2 VV-TMF-4175464
  Protocol  v 3.0  | 12  of 90
CONFIDENTIAL
Protocol        Date:  21 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN9536 -4578        Version:  3.0 Page:  13 of 90 
 
 Screening  Randomisation  Dose escalation period  Treatment period  End of 
treatment  End of 
trial 
Visit (V)  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 
Timing  of Visit (Weeks)  -1 0 4 8 12 16 20 28 36 44 52 60 68 75 
Visit  Window  (Days)  -7 to 0  ±0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +5  
     Dispensing  Visit   X  X  X X X X X X X   
     Drug  Accountability   X  X  X X X X X X X X  
REMINDERS                
Criteria  for discontinuation ( 7.1)    X X X X X X X X X X   
Barriers  and motivation  interview ( 8) X              
Diet and physical  activity  counselling ( 6.1.2 )  X X X X X X X X X X X X  
Training in the use of the pain and pain 
medication diary  X              
Review of the pain and pain medication diaryd 
(8.1.3 )  X X X X X X X X X X X X  
Hand  out direction  for use ( 6.1)  X             
Training  in trial product,  pen-handling   X X X X X X        
Hand  out dose reminder  card ( 6.1)  X X X X X X        
Hand  out ID card X              
a Demography consists of date of birth, sex, ethnicity, and race (according to local regulation).  
b Smoking is defined as smoking at least one cigarette or equivalent daily.  
c For all female subjects of child -bearing potential.  
d The pain and pain medication diary should be filled in on a daily basis by [CONTACT_17976]9536-4578 NN9536 0  |  . -  | 2 VV-TMF-4175464
  Protocol  v 3.0  | 13  of 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16874] significant public health c hallenges worldwide2-8. 
Obesity is associated with an increased risk of a variety of complications including osteoarthritis 
(OA), type 2 diabetes (T2D), dyslipi[INVESTIGATOR_17939], hypertension, cardiovascular disease, obstructive sleep 
apnoea, non -alcoholic fatty liver disease, urinary incontinence, several types of cancers, and 
increased m ortality.9-23 
The risk of obesity -related complications increases with incre asing body mass index (BMI) and 
body weight loss has been shown to have significant health benefits on many obesity -related 
complications as well as physical symptoms and health -related quality of life30-37. Lifestyle 
intervention in the form of diet and exercise is first line treatment for obesity, but most people with 
obesity struggle to achieve and maintain their weight loss38-47.  
With the increasing prevalence of obesity, the health issues related to knee OA will intensify with 
huge consequence for society and the individual patient. Obesity and the increased weight bearing 
are attributable to development and progressions of knee OA being a highly disabling degenerative 
joint disease22, 25. Due to the pi[INVESTIGATOR_17940], knee OA is 
associated with significant impairments and limitations to basic activities of daily living. The 
physical disability of knee OA arising from pain and loss of functional capacity reduces quality of 
life and increases the risk of further morbidity26.  
Weight loss is associated with a reduced risk of knee OA progression and improvement in pain and 
function regardless of the extent of radiological changes and knee OA grading27, 48, 49. However, in 
the IDEA trial only a reduction in baseline body weight of above 10% significantly reduced pain 
and improved function in subjects with knee OA and obesity27.  
Based on a systematic literature review, the ACR guidelines strongly recommends as primary 
management strategy that subjects with knee OA and obesity lose weight and participate in physical 
activity programme commensurate with their ability to perform these activities24. Furthermore, as 
obesity is an additional limiting factor in participating in physical acti vity programmes, weight loss 
will have both direct and indirect positive effect on management strategy and symptom relief in 
knee OA.   
2.[ADDRESS_16875] decreased 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 14 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  15 of 90 
 
quality of life, more pain and limited physical function compared to subjects with knee OA without 
obesity24.  
A reduction in baseline body weight loss above 10% significantly improves function and reduce 
pain in subjects with knee OA and obesity27. Semaglutide is a glucagon -like-peptide 1 (GLP -1) 
receptor agonist (RA) currently under development by [CONTACT_3454] A/S for weight management 
and treatment of obesity. Semaglutide is expected to provide a body weight loss of up to 10 -15%50. 
The aim of the present trial is to investigate the effects of semaglutide s.c. 2.4 mg once -weekly on 
weight loss, knee OA -related pain and physical function, and health -related quality of life in a 
patient population with obesit y and knee OA.  
2.2 Background  
2.2.1 Semaglutide  
Semaglutide is a long -acting GLP -1 RA currently under development by [CONTACT_3454] A/S for 
weight management. Semaglutide has a half -life of approximately [ADDRESS_16876] of semaglutide is 
mainly mediated by a reduced energy intake .  
A 52 -week phase 2 dose -finding trial within weight management (NN9536 -4153) has been 
completed. An overall monotone dose -dependent weight loss was observed across the 5 
semaglutide doses tested (0.05 to 0.4 mg once -daily). The estimated weight loss at week 52 was 
13.8% at the highest dose tested (0.4 mg once -daily) compared to the weight loss of 2.3% achieved 
by [CONTACT_17977], exercise and placebo alone50 . Base d on results from this trial, a target dose of 2.4 mg of 
semaglutide s.c. once -weekly was used for the clinical phase 3a and 3b programme50.   
The 68 -week phase 3a weight managem ent trial, STEP 1 (NN9536 -4373) has demonstrated clinical 
significant weight loss with semaglutide and is currently in the reporting phase. A total of 1,961 
subjects were included in the trial: 1,306 randomised to semaglutide s.c. 2.4 mg once -weekly and 
655 to placebo. At week 68, subjects in the semaglutide s.c. 2.4 mg once -weekly group achieved an 
average weight loss of 14.85% compared to 2.41% in the placebo group.  
A comprehensive review of results from the non -clinical and clinical studies of semagluti de can be 
found in the current edition of the investigator’s brochure (IB)50 and any updates hereof.  
2.3 Benefit -risk assessment  
Main benefits and risks are described in the below se ctions. More detailed information about the 
known and expected benefits and risks and reasonably expected adverse events of semaglutide may 
be found in the IB50 or any updates hereof.    
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 15 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  16 of 90 
 
2.3.1 Risk assessment  
Potential risk of clinical 
significance  
 Summary of data/rationale for 
risk 
 Mitigation strategy   
Trial treatment(s)  
Gastrointestinal AE  
 Consistent with findings with other 
GLP -[ADDRESS_16877] frequently 
reported adverse events (AE) in 
clinical trials with semaglutide were 
gastrointestinal AEs  (such as nausea, 
vomiting and diarrhoea). In general, 
these reactions are mild or moderate 
in severity, of short duration, and 
dose dependent.  
 
In subjects treated w ith GLP -[ADDRESS_16878] frequently reported gallbladder 
events in the clinical development 
programme for semaglutide 2.4 mg 
for weight management. In the phase 
3a trials cholelithiasis was reported 
in 1.6% and led to cholecystitis in 
0.6% of patients tr eated with 
semaglutide 2.4 mg.  If cholelithiasis is suspected, 
appropriate clinical follow -up is to 
be initiated at the investigator’s 
discretion  
Acute pancreatitis  Acute pancreatitis has been observed 
with the use of GLP -1 RA drug 
class.  The frequency of adjudication -
confirmed acute pancreatitis reported 
in phase 3a clinical trials was 0.2% 
for semaglutide 2.4 mg and <0.1% 
for placebo, respectively.  Subjects with a history of chronic 
pancreatitis or recent acute 
pancreatitis will not be enrolled in 
the trial. In addition, trial product 
should be discontinued in case of 
suspi[INVESTIGATOR_17941] 7.1 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 16 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  17 of 90 
 
Medullary thyroid cancer (MTC) 
(based on non -clinical data)  Proliferative thyroid C -cell changes 
were seen in the mouse and rat 
carcinogenicity studies after daily 
exposure to semaglutide for  2 years. 
No hyperplasia was observed in 
monkeys after 52 weeks exposure up 
to 13 -fold above the clinical plasma 
exposure at 2.4 mg/week. In clinical 
trials with semaglutide, there have 
been no clinically relevant changes 
in calcitonin levels. The C -cell 
changes in rodents are mediated by 
[CONTACT_17978] -1 receptor, which is not 
expressed in the normal human 
thyroid. Accordingly, the risk of 
GLP -1 receptor -mediated C -cell 
changes in humans is considered to 
be low.  Exclusion criteria related to medical 
history of m ultiple endocrine 
neoplasia type 2 (MEN2) or MTC 
have been implemented .  
Pancreatic cancer  There is currently no support from 
non-clinical studies, clinical trials or 
post-marketing data that GLP -[ADDRESS_16879] occurs.  
Neoplasms (malignant and non -
malignant)  Patients with overweight or obesity, 
have an increased risk of certain 
types of cancer. There is no evidence 
from clinical trials that GLP -1-based 
therapi[INVESTIGATOR_17942]. However, in  the 
semaglutide s.c. as well as oral 
semaglutide phase 3a trials for T2D, 
the proportion of subjects with 
neoplasms (malignant and non -
malignant) were slightly higher with 
semaglutide than with comparator. 
The number of subjects exposed to 
semaglutide s.c . or oral semaglutide 
for a longer period is considered 
insufficient for a thorough 
assessment of the risk of neoplasms.  Subjects with a history of malignant 
neoplasms within the past 5 years 
prior to screening will not be 
enrolled in this trial. Basal  
and squamous cell skin cancer and 
any carcinoma in -situ is allowed  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 17 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16880] an 
increased risk of infection or a more 
severe progression of infection when 
treated with semaglutide.  Detailed information about the 
known risks for semaglutide can be 
found in the investigator’s brochure . 
Trial procedures  
Pain analgesics washout period   There is a potential risk of increased 
pain  Washout period is short in duration. 
Use of rescue medication 
(acetaminophen) is allowed during 
wash out until [ADDRESS_16881] been taken:  
Cautious patient recruitment 
planning ensures controlled patient 
enrolment in countries where the 
COVID -[ADDRESS_16882] 
already during the protocol 
development been evaluated to limit 
the number of on -site visits. 
Additionally, we allow subjects that 
are treatment discontinued to conv ert 
on-site visits to phone (see Section 
7.1). 
Physical contact [CONTACT_17979], and protectiv e 
measures will be implemented 
according to local practice.  
Appendix 6 (Section 10.6) includes 
mitigations that can be implemented 
to ensure subject safety and data 
integrity in case a COVID -19 
outbreak leads to lock -down of sites 
which affects the ability to perform 
trial rel ated procedures.  
Other  
Pregnancy and fertility (based on 
non-clinical data)  Studies in animals have shown 
reproductive toxicity. There is 
limited data from the use of 
semaglutide in pregnant women.  Semaglutide should not be used 
during pregnancy. Exclusion and 
discontinuation criteria related to 
pregnancy have been implemented.  
AE, adverse events; GLP -[ADDRESS_16883]; MTC, medullary thyroid cancer; MEN2, 
multiple endocrine neoplasia type 2  
2.3.2 Benefit assessment  
Subjects will be treated with a regimen anticipated to be better than or equal to the weight 
management they receive at the time of entry into the trial. The 68 -week phase 3a weight 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 18 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  19 of 90 
 
management trials, STEP 1 (NN9536 -4373), have demonstrated clinically sign ificant weight loss 
with semaglutide s.c. 2.[ADDRESS_16884] of the trial in 
order to minimise the risks (including the risk of transmission of infectious diseases such as 
COVID -19) and inconveniences of participation in the trial. The safety profile for semaglutide 
generated from the clinical and non -clinical development programmes has not revealed any safety 
issues that would prohibit administration of semaglutide s.c. 2.4 mg once -weekl y. Results from four 
phase 3a trials with semaglutide s.c. 2.4 mg once -weekly (NN9536 -4373, -4374, -4375 and -4376) 
have demonstrated that semaglutide s.c. 2.4 mg once -weekly can provide a clinically meaningful 
weight loss. The anticipated benefits from di et and physical activity counselling will include all 
subjects participating in this trial.  
Taking into account the measures taken to minimise risk to subjects participating in this trial, the 
potential risks identified in association with semaglutide are justified by [CONTACT_17980].  
 
 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 19 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  20 of 90 
 
3 Objectives and endpoints  
3.1 Primary, secondary and exploratory objective(s) and estimand(s)  
Primary objectives  
To confirm superiority of semaglutide s.c. 2.[ADDRESS_16885] is: what is the average treatment effect of semaglutide s.c. 
2.[ADDRESS_16886] to a reduced -calorie diet and 
increased physical activity, in patients with obesity and knee OA, measured by [CONTACT_17981] 68 in body weight and knee OA -related pain, regardless of adherence to 
randomised treatment, regardless of initiating other anti -obesity therapi[INVESTIGATOR_014] (weig ht management 
drugs or bariatric surgery) or other knee OA interventions (joint replacement or steroid injection or 
opi[INVESTIGATOR_17943] ) and regardless of compliance with washout period for pain 
medication (the latter only relevant in th is context for knee OA -related pain) (“treatment policy” 
strategy).  
The estimand is described by [CONTACT_6570] (according to ICH E9(R1)):  
• Treatment condition: The randomised treatment regardless of adherence or initiation of other 
anti-obesity therapi[INVESTIGATOR_014] (as defined above) or other knee OA interventions (as defined above)  
• Population: Patients with obesity and knee OA  
• Endpoints: The two primary endpoints relative change in body weight and change in Western 
Ontario and McMaster Universities Osteoar thritis Index (WOMAC) pain score both from 
baseline to week 68  
• Remaining intercurrent events: The intercurrent events “treatment discontinuation for any 
reason”, “initiation of other anti -obesity therapi[INVESTIGATOR_014]” and “initiation of other knee OA 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 20 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  21 of 90 
 
interventions” are addressed by [CONTACT_17982]. The remaining intercurrent 
event is “compliance with washout period for pain medication” (in general only applicable to 
WOMAC endpoints), which is handled by [CONTACT_17983].  
• Population -level summary: Difference in mean changes between treatment conditions  
A similar estimand applies to all secondary endpoints (confirmatory and supportive), which is 
called secondary estimand. The population -level summary for body weight response endpoints is 
the ratio of odds between treatment conditions.  
Rationale for estimand: The primary (and secondary) estimand was requested by [CONTACT_17984] . 
Additional e stimand  
An additional clinical question of interest is: what is the average treatment effect of semaglutide s.c. 
2.[ADDRESS_16887] to a reduced -calorie diet and 
increased physical activity, in patients with ob esity and knee OA, measured by [CONTACT_17981] 68 in body weight and knee OA -related pain, had they remained on their 
randomised treatment for the entire planned duration of the trial, not initiated other anti -obesity 
therapi[INVESTIGATOR_014] (weight managem ent drugs or bariatric surgery) or other knee OA interventions (joint 
replacement or steroid injection or opi[INVESTIGATOR_17943] ) and had they 
additionally complied with the washout period for pain medication (the latter only relevant in th is 
context for knee OA -related pain) (“hypothetical” strategy).   
The estimand is described by [CONTACT_6570] (according to ICH E9(R1)):  
• Treatment condition: The randomised treatment if patients had adhered for the entire duration of 
the trial, no t initiated other anti -obesity therapi[INVESTIGATOR_014] (as defined above) or other knee OA 
interventions (as defined above)  
• Population: Patients with obesity and knee OA  
• Endpoints: The two primary endpoints relative change in body weight and change in WOMAC 
pain score b oth from baseline to week 68  
• Remaining intercurrent events: The intercurrent events “treatment discontinuation for any 
reason”, “initiation of other anti -obesity therapi[INVESTIGATOR_014]” and “initiation of other knee OA 
interventions” are addressed by [CONTACT_17985]. The remaining intercurrent 
event is “compliance with washout period for pain medication” (in general only applicable to 
WOMAC endpoints), which is handled by [CONTACT_17986].  
• Population -level summary: Difference in mean changes b etween treatment conditions  
A similar additional estimand also applies to all secondary body weight endpoints as well as all 
secondary WOMAC endpoints (both confirmatory and supportive). The population -level summary 
for body weight response endpoints is th e ratio of odds between treatment conditions.  
Rationale for estimand: The additional estimand was requested by [CONTACT_17987].  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 21 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  22 of 90 
 
3.2 Primary, secondary and exploratory endpoint(s)  
3.2.1 Primary endpoints  
Endpoint title  Time frame  Unit 
Change in body weight  From baseline (week 0) to end of 
treatment (week 68)  % 
Change in WOMAC pain score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
WOMAC; Western Ontario  and McMaster Universities Osteoarthritis Index  
3.2.2 Secondary endpoints  
The confirmatory and supportive secondary endpoints addressing the primary and secondary 
objectives are listed in Sections [IP_ADDRESS]  and [IP_ADDRESS] . 
[IP_ADDRESS]  Confirmatory secondary endpoints  
Endpoint title  Time frame  Unit 
Achieving body weight reduction 
≥5% (yes/no)  From baseline (week 0) to end of 
treatment (week 68)  Count of subject  
Achieving body weight reduction 
≥10% (yes/no)  From baseline (week 0) to end of 
treatment (week 68)  Count of subject  
Change in WOMAC physical 
function score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 physical 
functioning score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
WOMAC; Western Ontario and McMaster Universities Osteoarthritis Index, SF -36; Short Form (36) Health Survey  
[IP_ADDRESS]  Supportive secondary endpoints  
Endpoint title  Time frame  Unit 
Change in waist circumference  From baseline (week 0) to end of 
treatment (week 68)  cm 
Change in WOMAC stiffness score  From baseline (week 0) to end of 
treatment (week 68) Score points  
Change in WOMAC total score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 bodily pain score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 physical 
component summary  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 mental 
component summary  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Use of allowed rescue analgesics 
during wash out  From baseline (week 0) to end of 
treatment (week 68)  Count of subjects  
Amount of allowed rescue 
analgesics used during wash out  From baseline (week 0) to end of 
treatment (week 68)  Dose  
Change in pain medication  From baseline (week 0) to end of 
treatment (week 68)  Dose  
Change in pai n intensity (NRS)  From baseline (week 0) to end of 
treatment (week 68)   Score points  
WOMAC; Western Ontario and McMaster Universities Osteoarthritis Index, SF -36; Short Form (36) Health Survey  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 22 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  23 of 90 
 
3.2.3 Exploratory endpoint(s)  
Endpoint title  Time frame  Unit 
Change in 6 minutes walking 
distance  From baseline (week 0) to end of 
treatment (week 68)    Meters  
Change in SF -36 role -physical 
score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 general health 
score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 vitality score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 social functioning 
score  From baseline (week 0) to end of 
treatment (week 68)  Score point s 
Change in SF -36 role -emotional 
score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
Change in SF -36 mental health 
score  From baseline (week 0) to end of 
treatment (week 68)  Score points  
 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 23 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  24 of 90 
 
4 Trial design  
This trial is designed to evaluate weight loss and knee OA -related outcomes and will apply a 
targeted approach to collection of safety data focusing on serious adverse events (SAEs), adverse 
events (AEs) leading to discontinuation of trial product and othe r selected AEs. An adequate 
characterisation of the less serious and more common AEs is evaluated in the phase 3a trials 
(Section 2.2.1 ).  
4.1 Overall design  
This is a 68 -week, randomised, two -arm, double -blinded, multi -centre clinical trial comparing 
semaglutide s.c. 2.4 mg once -weekly with semaglutide placebo in subjects with moderate OA of 
one or both knees, pain due to knee OA, and obesity (BMI ≥30.0  kg/m2). 
Eligible subjects will be randomised in a 2:[ADDRESS_16888] to a reduced -calorie diet and increased 
physical activity ( Figure  4-1).  
 
The trial includes a screening visit to assess the subject’s eligibility followed by [CONTACT_17988] 8th week until end -of-treatment (week 68). Follow -up period is 7 weeks af ter end -of-treatment  
(week 75).  
mg; milligram  
Figure  4-[ADDRESS_16889] of subjects with obesity (≥ BMI 30.0  kg/m2) and knee OA 
((primary knee OA according to the ACR criteria), ≥ 40 point in the WOMAC pain subscale, and 
radiological KL grade 2 or 3)59. The trial population is chosen to optimise the likelihood of 
achieving a clinical benefit with weight loss (reduction in knee OA -related pain and improved 
physical function) by [CONTACT_17989] a clear medical need (obesity and knee OA). Although 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 24 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  25 of 90 
 
T2D is prevalent in the obesity p opulation, it has been decided to exclude this group of subjects 
from the trial in order to get a homogenous study population.  
The treatment duration of the trial is 68 weeks with an additional 7 weeks follow -up (without 
treatment). A 68 -week treatment dur ation (including 52 weeks on target dose) is considered 
sufficient to realise the weight loss potential of the intervention as well as downstream effects on 
symptoms and function related to knee OA. The [ADDRESS_16890] to a reduced calorie diet and increased physical activity.  
In accordance with guideline for Clinical investigation of medicinal products used in the treatment 
of OA by [CONTACT_3558] (EMA) pain medication required during the trial period 
is discontinued 72 hours in advance of assessment of symptomatic endpoints to avoid confounding 
effects60. During the washout rescue medication wit h acetaminophen is allowed as analgesic until 
24 hours before visit if needed.  
4.3 Justification for dose  
Results from the phase 2 dose -finding trial for semaglutide in weight management (NN9536 -4153) 
showed that the semaglutide s.c. 0.[ADDRESS_16891] effective in terms of weight loss 
while displaying an acceptable tolerability profile. Using population pharmacokinetic modelling, it 
was estimated that a once -weekly maintenance dose of semaglutide s.c. 2.4 mg will result in similar 
Cmax at steady -state as that obtained by [CONTACT_17990] -daily 0.4 mg semaglutide dose in trial 
NN9536 -4153.  
A maintenance dose of semaglutide s.c. 2.4 mg once -weekly was chosen for the phase 3 weight 
management development programme. The once -weekly dosing is anticipated to ea se the burden of 
drug administration in clinical practice. Subjects will be initiated at a once -weekly dose of 0.24 mg 
and follow a fixed -dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 
1.7 and 2.4 mg/week), until the targ et dose is reached after [ADDRESS_16892] in the trial globally.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 25 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  26 of 90 
 
5 Trial population  
Prospective app roval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 Inclusion criteria  
Subjects are eligible to be included in the trial only if all of the following criteria apply:  
1. Informed consent obtained before any trial -related activities. Trial -related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability 
for the trial  
2. Male or female, age above or equal to 18 years at the t ime of signing informed consent  
3. Body Mass Index (BMI) ≥30.0 kg/m2  
4. Clinical diagnosis of knee OA (ACR criteria) with moderate radiographic changes (KL 
grades 2 or 3 as per central reading) in target knee. Target knee joint is defined as most 
symptomatic kn ee at screening. If pain in knees are equal target knee joint will be in the most 
dominant leg.  
5. Pain due to knee OA (Section 5.5.1 ) 
6. Willingness to co mplete 72 -hour washout period of analgesics before all visits involving 
WOMAC questionnaire (acetaminophen is allowed as rescue medication).  
5.2 Exclusion criteria   
Subjects are excluded from the trial if any of the following criteria apply:  
 
Knee OA -related:  
1. Joint replacement in target knee  
2. Arthroscopy or injections into target knee within the last 3 months prior to enrolment  
3. Elective surgery scheduled during the trial duration period, except for minor surgical 
procedures  
4. Any other joint disease in the target  knee  
5. Current u se of medical marijuana or opi[INVESTIGATOR_2438]  
6. Symptomatic hip OA unless treated with hip replacement  
7. Primary localisation of pain is not within target knee  
8. Chronic widespread pain, including neuropathic pain  
 
Obesity -related:  
9. Previous or planned (during the trial period) obesity treatment with surgery or a weight loss 
device, except for: (1) liposuction and/or abdominoplasty, if performed > 1 year before 
screening, (2) lap banding, if the band has been removed >1 year before sc reening, (3) 
intragastric balloon, if the balloon has been removed >1 year before screening or (4) 
duodenal -jejunal by[CONTACT_17991], if the sleeve has been removed >1 year before screening.  
10. A self -reported change in body weight > 5 kg (11 lbs) within [ADDRESS_16893] 90 days before 
screening  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 26 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  27 of 90 
 
Glycemia -related:  
13. HbA 1c ≥ 48 mmol/mol (6.5%) as measured by [CONTACT_17992] y at screening  
14. History or presence of type 1 or type 2 diabetes (history of gestational diabetes is allowed)  
15. Treatment with any GLP -1 RA within 90 days prior to the day of screening  
 
General health and safety:  
16. Personal or first -degree relative(s) history o f multiple endocrine neoplasia type [ADDRESS_16894] 60 days prior to screening: myocardial infarction, stroke, 
hospi[INVESTIGATOR_17944]  
22. Subjects presently classified with heart failure [LOCATION_001] Heart Association: Class IV  
23. Known or su spected hypersensitivity to trial product(s) or related products  
24. Previous participation in this trial. Participation is defined as signed informed consent  
25. Participation in another clinical trial within [ADDRESS_16895](s) from the same household participating in any semaglutide trial  
27. Female who is pregnant, breast feeding or intends to become pregnant or is of child -bearing 
potential and not using a highly effective contraceptive method (highly effective 
contraceptive measures as r equired by [CONTACT_17993])  
28. History of major depressive disorder within 2 years before screening  
29. Diagnosis of other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder)  
30. History of a suicide attempt  
31. Suicidal behaviour within 30 days before screening  
32. Known or suspected abuse of alcohol or recreational drugs  
33. Any disorder, unwillingness or inability, not covered by [CONTACT_17994], 
which in the investigator’s opi[INVESTIGATOR_1649], might jeopardis e the subject’s safety or compliance with 
the protocol  
a Simultaneous participation in a trial with the primary objective of evaluating an approved or non -approved 
investigational medicinal product for prevention or treatment of COVID -[ADDRESS_16896] has been received more than 30 days before screening.  
 
The criteria will be assessed at the investigator’s discretion unless otherwise stated.  
 
For country specific req uirements, see  Appendix 7 (Section 10.7)  and for contraceptive 
requirements, see  Appendix 4 (Section 10.4). 
5.3 Lifestyle considerations  
To ensure alignment regarding performance of assessments across subjects and trial sites, the below 
restrictions apply.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 27 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16897] 30 minutes prior to measuring their blood 
pressure.  
5.4 Screen failures  
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
eligible for participation according to inclusion/exclusio n criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet 
requirements from regulatory authorities. Minimal information includes informed consent date, 
demography, screen failure details, eligibility criteria, and any SAEs. A screen failure session must 
be made in the interactive web response system (IWRS).  
Individuals who do not meet the criteria for participation in this trial may not be rescreened. If the 
subject has failed one of the inclusion criteria or fulfilled one of the exclusion criteria related to the 
laboratory parameter, re -sampling is not allowed. However, in case of technical issues (e.g. 
haemolysed or lost), re -sampling is allowed for the affected parameters . If the  subject has failed 
inclusion criteria no. [ADDRESS_16898] 40 on the WOMAC version 3.1 pain subscale (range 0 -100 normalised 
Numerical Rating Scale ( NRS))  
2. For subjects taking analgesics, attend randomisation visit after 72 -hour washout period 
(rescue medication with acetaminophen allowed until 24 hours before visit) (Section 8.1.1 )  
To be randomised, all relevant randomisation criteria must be answered "yes".  
A subject not fulfilling the randomisation criteria will be considered a randomisation failure, see 
Section 5.4 regarding screen failures.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 28 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  29 of 90 
 
6 Treatments  
6.1 Treatments administered  
• All trial products listed in Table  6-1 are considered investigational medicinal products 
(IMP).  
• Trial product must only be used, if it appears clear and colourless.  
 
Table  6-[ADDRESS_16899] provided by [CONTACT_3454] A/S  
Trial  product name:  [CONTACT_18055] B 3.0 mg/mL PDS290   Semaglutide Placebo  
Dosage form  Solution for injection  Solution for injection  
Route of administration  Subcutaneous  Subcutaneous  
Dosing instruction:  Once -weekly  Once -weekly  
Delivery device  3 mL PDS290 pre-filled pen -injector  3 mL PDS290 pre -filled pen -injector  
• Dose escalation of semaglutide/semaglutide placebo should take place during the first 16 weeks 
after randomisation as described in Table  6-2. All subjects should aim at reaching the 
recommended target dose of 2.4 mg semaglutide s.c. once -weekly or the corresponding volume 
of semaglutide placebo.  
• If a subject does not tolerate the recomm ended target dose of 2.[ADDRESS_16900], as per the investigator’s discretion. It is recommended that the 
subject makes at least one attempt to re -escalate to the recommended target dose of 2.4 mg 
semaglutide s.c. once -weekly, as per the investigator’s discretion.  
• It is recommended that the investigator consults Novo Nordisk in case of persistent deviations 
from the planned escalation regimen.  
• The investigator must document that directions for use are given to the subject verbally and in 
writing at the first dispensing visit (as spec ified in the flowchart).  
• A dose reminder card will be handed out to the subjects at each site visit during the dose 
escalation period. This is to remind the subjects of the dose to be taken until next site visit and 
provide a conversion of the dose to valu e shown in the dose counter. Once the target dose has 
been reached, the dose reminder card is only handed out as needed.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 29 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  30 of 90 
 
Table  6-2 Dose escalation and maintenance of semaglutide s.c. 2.4 mg /semaglutide place bo 
once -weekly  
Trial product name  [CONTACT_18056] B 3.0 mg/mL 
PDS290 or semaglutide placebo  0.24 mg  8* 4 weeks  
Semaglutide B 3.0 mg/mL 
PDS290 or semaglutide placebo  0.5 mg  17* 4 weeks  
Semaglutide B 3.0 mg/mL 
PDS290 or semaglutide placebo  1.0 mg  34* 4 weeks  
Semaglutide B 3.0 mg/mL 
PDS290 or semaglutide placebo  1.7 mg  57* 4 weeks  
Maintenance period  
Semaglutide B 3.0 mg/mL 
PDS290 or semaglutide placebo  2.4 mg  80* 52 weeks  
*Conversion to dose is calculated based on 0.01 ml/value  
• Subjects will be instructed to inject semaglutide/semaglutide placebo once -weekly at the same 
day of the week (to the extent possible) throughout the trial.  
• Injections may be administered in the thi gh, abdomen or upper arm, at any time of day 
irrespective of meals.  
• If a single dose of trial product is missed, it should be administered as soon as noticed, provided 
the time to the next scheduled dose is at least 2 days (48 hours). If a dose is missed a nd the next 
scheduled dose is less than 2 days (48 hours) away, the subject should not administer a dose 
until the next scheduled dose. A missed dose should not affect the scheduled dosing day of the 
week.  
• If ≥ [ADDRESS_16901] should be encouraged to 
recommence the treatment if considered safe as per the investigator’s discretion and if the 
subject does not meet any of the discontinuation criteria (Section 7.1). The trial product should 
be continued as early as the situation allows. The missed doses should not affect the scheduled 
dosing day of the week. The start dose for re -initiation of trial pro duct is at the investigator’s 
discretion. In case of questions related to re -initiation of trial product, the investigator should 
consult Novo Nordisk global medical expert.  
Auxiliary supplies  
• Auxiliary supplies will be provided in accordance with the tri al materials manual (TMM) please 
see Table  6-3. 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 30 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  31 of 90 
 
Table  6-3 Auxiliary supplies provided by [CONTACT_3454] A/S  
Auxiliary supply  Details  
Needles  Needles for pre -filled pen system. Details provided in the 
TMM  
Only needles provided and approved by [CONTACT_17995].  
Directions for use (DFU)  DFU for 3 ml PDS290 pre -filled pen -injector.  
Not included in the dispensing unit and to be handed out 
separately.  
 
6.1.1 Medical devices  
Information about the PDS290 pre -filled pen -injector may be found in the IB50 and any updates 
hereof.  
Information about the use of the PDS290 pre -filled pen -injector for semaglutide 3.0 mg/mL and 
semaglutide placebo can be found in the DFU.  
Training in the PDS290 pre -filled pen -injector  
The investi gator must document that training in the DFU has been given to the subjects verbally and 
in writing at the first dispensing visit. Training must be repeated, during the trial at regular intervals 
in order to ensure correct use of the medical device. Traini ng is the responsibility of the investigator 
or a delegate.  
6.1.2 Diet and Physical Activity counselling  
All subjects in both treatment arms will receive counselling with regards to reduced calorie diet and 
physical activity taking subjects knee OA into conside ration. Counselling should be done by a 
dietician or a similar qualified healthcare professional  
[IP_ADDRESS]  Non-investigational medical device(s)  
Non-investigational medical devices are listed in Section 6.1 as auxiliary supplies.  
6.2 Preparation/handling/storage/accountability  
Only subjects randomised to treatment may use trial product and only delegated site staff may 
supply or administer trial prod uct. 
Table  6-[ADDRESS_16902] name  [CONTACT_18057]  
(not-in-use) In-use conditions  In-use time 
Semaglutide B 3.0 mg/mL 
PDS290   Store in refrigerator (2°C -
8°C/36°F -46°F)  
Do not freeze  
Protect from light  In-use conditions will be 
available on the trial 
product label  In-use timea will be 
available on the trial 
product label  Semaglutide placebo  
aIn-use time starts when the product is taken out of the refrigerator in the subject’s home  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 31 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  32 of 90 
 
• Each site will be supplied with enough trial products for the trial on an ongoing basis. Trial 
product will be distributed to the sites according to screening and randomisation . 
• The investigator or designee must confirm that appropriate tem perature conditions have 
been maintained during transit for all trial products received, and that any discrepancies are 
reported and resolved before use of the trial products.  
• All trial products must be stored in a secure, controlled, and monitored (manual  or 
automated) area in accordance with the labelled storage conditions with access limited to the 
investigator and delegated site staff.  
• The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditions. The trial product must not be dispensed to any subject before it 
has been evaluated and approved for further use by [CONTACT_3454]. Additional details 
regarding handling of temperature deviations can be found in the TMM.  
• The investigator or desig nee is responsible for drug accountability and record maintenance 
(i.e. receipt, accountability and final disposition records).  
• The investigator or designee must instruct the subject in what to return at next visit.  
• Drug accountability should be performed on a pen level and must be documented in the 
IWRS.  
• The subject must return all used, partly used and unused trial product including empty 
packaging materials during the trial as instructed by [CONTACT_093].  
• Destruction of trial products can be perform ed on an ongoing basis and will be done 
according to local procedures after accountability is finalised by [CONTACT_17996].  
• All returned, un -used, expi[INVESTIGATOR_17945] (for technical complaint samples, 
see Section 10.5) must be stored separately from non -allocated trial products. No 
temperature monitoring is required.  
• Non-allocated trial products including expi[INVESTIGATOR_5697] o r damaged products must be accounted as 
unused, at the latest at closure of the site.  
6.2.[ADDRESS_16903]’s home  
For selected countries and if permitted by [CONTACT_427], the investigator may offer to send trial 
product and auxiliaries from the trial site or pharmacy to the subject’s home by [CONTACT_17997].  
The process for sending trial product from the trial s ite or pharmacy to a subject’s home is 
described in the “Trial site/pharmacy instruction for shipment of trial product to patients’ homes” 
document. The document contains detailed instructions for preparing packaging and setting up the 
pi[INVESTIGATOR_9696]-up of trial pro duct, handover of trial product from the trial site or pharmacy staff to the courier, 
required temperature monitoring of trial product, delivery to and receipt of trial product by [CONTACT_4677]. The process for returning trial product to the trial site or ph armacy by [CONTACT_17998].  
Investigators, trial site/pharmacy staff and patients who will be involved in shipment of trial product 
to the subject’s home will be adequately trained in this process.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 32 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  33 of 90 
 
6.3 Measures to minimise bias: Rand omisation and blinding  
Randomisation  
• All subjects will be centrally screened and randomised using an IWRS and assigned to the 
next available treatment according to randomisation schedule. Trial product will be 
dispensed at the trial visits summarised in th e flowchart.  
Blinding  
• The active drug and placebo are visually identical for the following trial products:  
o Semaglutide B 3.0 mg/mL PDS290/Semaglutide placebo  
• The IWRS is used for blind -breaking. In case of an emergency, the investigator has the sole 
respon sibility for determining if unblinding of a subjects’ treatment is warranted. Subject 
safety must always be the first consideration in making such a determination. If the 
investigator decides that unblinding is warranted, the investigator should make every  effort 
to contact [CONTACT_17999] a subjects’ treatment unless this could delay 
emergency treatment of the subject. If a subject’s treatment is unblinded, Novo Nordisk 
(Global Safety department) must be notified within [ADDRESS_16904] print the “code break confirmation” notification 
generated by [CONTACT_8784], sign and date the document. If IWRS is no t accessible at the time of 
the blind break, the IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_18000] [ADDRESS_16905](s) at home, compliance with trial product administration 
will be assessed and the assessment documented in source documents at each visit where 
information is available. If any suspi[INVESTIGATOR_17946] -compliance arises,  the site must enter into a 
dialogue with the subject, re -emphasizing the importance of compliance and uncover barriers to 
compliance. This dialogue must be documented. Treatment compliance of trial product will be 
assessed by [CONTACT_18001]. 
Information on treatment dose and periods > 14 days without treatment will be recorded in the case 
report form (CRF).  
6.[ADDRESS_16906] be recorded along with:  
• Trade name [CONTACT_18058]  
• Indication  
• Dates of administration including start and stop dates  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 33 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
Status:  Final  
Page:  34 of 90 
•For analgesics, subjects must record dose and frequency in the  pain medication diary
provided
During the trial subjects should not initiate any anti-obesity treatment (e.g. medication) which is not 
part of the trial procedures. If such treatment is initiated, the subject should be instructed to stop the 
anti-obesity treatment. 
All pain medications are allowed during the trial, except for the use of opi[INVESTIGATOR_17947] (Section  5.2). Initiation of opi[INVESTIGATOR_17948]. If such 
treatment is initiated, the subject should be instructed to stop the opi[INVESTIGATOR_2512], and all other 
options must be tried before starting opi[INVESTIGATOR_2495] d medication. During the washout period (24 –  72 h 
before visits), subj ects s
hould not use any pain medication, with the exception of acetaminophen, 
and should not use any pain medication <[ADDRESS_16907] be reported according to Secti on 8.3. 
6.5.1 Rescue medication 
During the washout period , use of acetaminophen for rescue medication (maximum of 4 g/day) is 
allowed until 24 hours before visit. Use of acetaminophen ( dose and frequency)  has to be recorded 
by [CONTACT_18002] . 
Rescue medication will not be supplied or reimbursed by [CONTACT_3454]. 
6.6 Dose modification  
Not applicable for this trial. Please refer to Section 6.1 for description of missed dose(s). 
6.7 Treatment after end of trial  
•There is no treatment following the end of trial.
•When discontinuing trial products, the subject should be transferred to a suitable marketed
product at the discretion of the investigator.
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 34 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16908]  
discontinuation/withdrawal  
Treatment of a subject may be discontinued at any time during the trial at the discretion of the 
investigator  for safety, behavioural, compliance or administrative reasons.  
Efforts must be made to have subjects, who discontinue trial product, to continue in the trial. 
Subjects must be educated about the continued scientific importance of their data, e ven if they 
discontinue trial product. Only subjects who withdraw consent will be considered as withdrawn 
from the trial.  
7.1 Discontinuation of trial treatment  
• Discontinuation of treatment can be decided by [CONTACT_18003].  
• Subjects who  discontinue trial product should continue with the scheduled visits and 
assessments to ensure continued counselling and data collection.  
o If the subject does not wish to attend the scheduled clinic visits efforts should be 
made to have the visits converte d to phone contacts. However, all effort should be 
made to have the subject attend at least the ‘end of treatment’ clinic visit containing 
the final data collection of primary and confirmatory secondary efficacy endpoints, 
and the ‘end of trial’ visit.  
• The 'end of trial' visit is scheduled approximately [ADDRESS_16909] > 7 weeks prior 
to the 'end of treatment' visit, and the requirements for the foll ow-up period prior to the 'end 
of trial' visit is fulfilled, then 'end of trial' visit can be performed in combination with 'end of 
treatment' visit.  
o If the subject refuses to attend the ‘end of treatment’ and/or ‘end of trial’ visit, 
information about th e attempts to follow up with the subject must be documented in 
the subject’s medical record.  
The trial product must be discontinued, if any of the following applies for the subject:  
1. Safety concern as judged by [CONTACT_093]  
2. Suspi[INVESTIGATOR_17949] 
3. Pregnancy  
4. Intention of becoming pregnant  
5. Simultaneous use of an approved or non -approved IMP in another clinical triala 
a Simultaneous participation in a trial with the primary objective of evaluating an approved or non -approved 
investigational medicin al product for prevention or treatment of COVID -19 disease or postinfectious conditions is 
allowed at the investigator’s discretion without discontinuing trial product.  
If acute pancreatitis is suspected appropriate actions should be initiated, including l ocal 
measurements of amylase and lipase (see  Appendix 3 (Section 10.3) for reporting).  
 
Subjects meeting discontinuation of trial product criterion no. [ADDRESS_16910] may be resumed for subjects with a 
gallstone -induced pancreatitis in case of cholecystectomy.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 35 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16911], if the criteria are no longer met (Section 7.1.1).  
The primary reason for discontinuation of trial product must be specified in the end -of-treatment -
form in the CRF, and final drug accountability must be performed. A treatment discontinuation 
status session must be made in the IWRS to indicate  discontinuation of trial product.  
7.1.[ADDRESS_16912] should follow the guide for misse d doses 
(Section  6.1). Similarly, a subject who discontinues trial product on their own initiative should be 
encouraged to resume trial product (Section 6.1).  
If a ‘treatment’ status session previously has been made in IWRS to indicate discontinuation of trial 
product, a new ‘treatment status’ session must be made to resume trial product.  
7.1.[ADDRESS_16913] discontinuation/withdrawal from the trial  
A subject may withdraw consent at any time  at his/her own request.  
If a subject withdraws consent, the investigator must ask the subject if he/she is willing, as soon as 
possible, to have assessment performed according to the ‘end of treatment’ visit. See the flowchart 
for data to be collected.  
Final drug accountability must be performed even if the subject is not able to come to the site. A 
treatment discontinuation status session must be made in the IWRS to indicate discontinuation of 
trial product.  
If the subject withdraws consent, Novo Nordisk may retain and continue to use any data collected 
before such a withdrawal of consent.  
If a subject withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the investigator must document this in the medical record.  
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where 
the reasons are obtained, the primary reason for wit hdrawal must be specified in the end of trial 
form in the CRF.  
7.2.[ADDRESS_16914] or withdraw from trial will not be replaced.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 36 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16915] fails to return to the site for a required visit:  
• The site must attempt to contact [CONTACT_18004]/or should continue in the 
trial. 
• Before a subject is deemed lost to follow -up, the investiga tor or designee must make every 
effort to regain contact [CONTACT_1155] (where possible, at least three telephone calls and, if 
necessary, a certified letter to the subject's last known mailing address or local equivalent 
methods). These contact [CONTACT_18005]'s source document.  
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the trial with a primary reason of ‘lost to follow -up’. 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 37 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  38 of 90 
 
8 Trial assessments and procedures  
• The following sections describe the assessments and procedures, while their timing is 
summarised in the flowchart.  
• Informed consent must be obtained before any trial -related activity, see Section 10.1.3 . 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all inclusion criteria and none of the exclusion criteria.  
• The investigator will maintain a screening log to record details of all subjects screened and 
to confirm eligibility or record reason for screen failure, as applicable.  
• At screening, subjects will be provided with a card stating that they are participating in a 
trial and giving contact [CONTACT_18006] s taff that can be contact[CONTACT_18007].   
• Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct.   
• Assessments should be carried out according to the clinic’s standard of practice unless 
otherwise specified in the current section. Efforts should be made to limit the bias between 
assessments.  
• Source data of clinical assessments performed and recorded in the CRF must be available 
and will usually be the subject’s medical rec ords. Additional recording to be considered 
source data includes, but is not limited to laboratory reports, clinical outcome assessments.  
• The barriers and motivation interview identify barriers to and motivation for lifestyle change 
and compliance with th e protocol. The interview must be conducted at screening to assist in 
identifying subjects who are unable or unwilling to comply with protocol procedures as per 
the exclusion criteria. In addition, the interview will ensure that any minor barriers are 
addressed during lifestyle counselling.  
o The results of the interview will not be entered into the CRF. It will be at the 
investigator’s discretion to evaluate the motivation of the subject and related 
eligibility.  
• Subject’s weight history must be recorded in  the subject’s medical record.  
• Review of pain and pain medication  diary, patient reported outcome (PRO) instruments, 
laboratory report etc. must be documented either on the documents or in the subject's source 
documents. If clarification of entries or disc repancies in the PRO instruments is needed, the 
subject must be questioned, and a conclusion made in the subject's source documents. Care 
must be taken not to bias the subject.  
• Repeat samples may be taken for technical issues and unscheduled samples or ass essments 
may be taken for safety reasons. Please refer to  Appendix 2 (Section 10.2) for further details 
on laboratory samples.  
8.1 Efficacy assessments   
Planned time points for all efficacy assessments are provided in the flowchart.  
8.1.1 Western Ontario and McMaster Universities Osteoarthritis Index   
Subjects should be given the opportunity to complete the questionnaire by [CONTACT_18008]. The questionnaire takes approximately 5 -10 minutes to complete62.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 38 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  39 of 90 
 
• The WOMAC Osteoarthritis Index is a tri -dimensional, disease -specific, patient -reported 
outcome (PRO) measure63. It probes clinically -important, patient -relevant symptoms in the 
area of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or 
knee. The index consists of 24 questio ns (5 pain, 2 stiffness, 17 physical function).  
• The version used is the WOMAC 3.1 NRS version, an 11 -point numeric rating scale with 
responses ranging from no symptom/difficulty (0) to extreme symptom/difficulty (10). The 
version used has a 24 -hour recall period.  
• Subscale scores for pain, stiffness and physical function and a total score will be calculated 
according to the guidelines provided in the WOMAC user manual.  
• For subjects taking analgesics, no analgesics with exception of acetaminophen until 
24 hours before visit, may be taken 72 -hours prior to completing the questionnaires allowing 
for 72 -hour washout.  
• WOMAC questionnaire will relate to target knee joint defined as most symptomatic knee at 
screening. If pain in knees are equal target knee joint w ill be in the most dominant leg.  
8.1.2 Body measurements  
• Body weight should be measured without shoes, on an empty bladder and only wearing light 
clothing. It should be measured on a digital scale and recorded in kilograms or pounds (one 
decimal) using the same  scale throughout the trial.  
• The scale must be calibrated yearly as a minimum.  
• Height is measured without shoes in centimetres or inches (one decimal). BMI will be 
calculated by [CONTACT_18009]. 3.  
• Waist circumference is defined as:  
o abdominal circumference located midway between the lower rib margin and the iliac 
crest  
o Measures must be obtained in a standing position with a non -stretchable measuring 
tape and to the nearest cm or inch.  
o The tape shoul d touch the skin but not compress soft tissue and twists in the tape 
should be avoided. The subject should be asked to breathe normally. The same 
measuring tape should be used throughout the trial. The measuring tape will be 
provided by [CONTACT_18010].  
8.1.[ADDRESS_16916] their : 
• daily pain in the knee  at its worst (NRS) .  
• daily  use of pain medication  and rescue pain medication  (acetaminophen) , including dose and 
frequency .  
The investigator/site staff should review the diary for missing entries . The investigator should assist 
the subject in choosing the pain medication most often used and assist in choosing the correct 
category if the subject has chosen the category ‘Other’. If the subject has not taken any pain 
medication, this has to be recorded  in the diary.  Use of pain medication should also be reflected in 
EDC (standard concomitant medication form) . 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 39 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16917] should be given the opportunity to complete the questionnaires by [CONTACT_18008]. Each questionnaire takes approximately 10 minutes to complete.  
The following PROs will be used:  
• The WOMAC  3.1 NRS  (Section 8.1.1 )  
• Patient Global Impression of Status (PGI -S) for Pain  
• Patient Global Impress ion of Change (PGI -C) for Pain  
• Short Form 36 v2 .0 acute (SF -36) 
The SF-36v2.0 is a 36-item commonly used generic PRO instrument measur ing health -related 
quality of li fe and general  health status across disease areas. The SF -36v2.0 for adults with a 
1 week recall period (i.e. acute version) measures the individual overall health -related quality of 
life in 8 health domains (physical functioning, role limitation due to physical health problems 
[role -physical], bodily pain, general health, social functioning, role limitations due to emotional  
problems [role -emotional], vitality and mental health). F urthermore, it includes 2 aggregated  
scores: a physical component summary score and a mental component summary score64.  
• PGI-S for physical function  
• PGI-C for physical function  
• Knee pain NRS item  
      This is a single item measuring knee pain at its worst in the last 24 hours. This item is the pain 
diary described in Section 8.1.3 . The response scal e is a 11 -point numeric rating scale from 0 
(No knee pain) to 10 (Worst possible knee pain).  The NRS item  will relate to the target knee 
joint defined as the most symptomatic knee at screening. If pain in the knees are equal , the 
target knee joint will be in the most dominant leg.  
• [ADDRESS_16918] (6MWT)  
The 6MWT assesses the distance a subject can walk in [ADDRESS_16919] of 66 feet ( 20 m) ( Figure  8-1). The primary outcome is 
the distance covered over [ADDRESS_16920] administration criteria are met 
(e.g., the test is assessed along a flat, straight, undisturbed room that is at least 6 feet (1.8 m) 
wide; proper footwear as judged by [CONTACT_18011] w orn by [CONTACT_18012])67. 
If the specific test administration criteria are not met, the 6MWT should not be performed.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 40 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16921] experienced prior to the time point from which 
AEs are coll ected. Only relevant and significant medical history as judged by [CONTACT_18013]. Findings of specific medical history should be described in the Medical 
History/Concomitant Illness form.  
The following concomitant illness/medical histo ry should be recorded in the eCRF:  
• History of breast neoplasm  
• History of cardiovascular disorder and procedure  
• History of dyslipi[INVESTIGATOR_035]  
• History of gallbladder disease and procedure  
• History of gastrointestinal disorder and neoplasm  
• History of musculoskeletal  system disorder  
• History of pancreatic disease  
• History of psychiatric disorder  
• History of skin cancer and skin disorder  
• History of weight disorder  
• Other relevant concomitant illness/medical history including COVID -[ADDRESS_16922] the finding on the Medical History/ 
Concomitant Illness form.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 41 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  42 of 90 
 
8.2.1 Radiographic examinations  
• Results o f a radiographic examination of the target knee, performed by a suitably qualified 
health care provider, will be evaluated by [CONTACT_18014]. Results will be made available to 
the investigator before randomisation to assess eligibility.  
• If the subject ha s had a radiographic examination performed within [ADDRESS_16923] examination.  
• The radiographs will be assessed using the KL grading system; a categorical grading scale 
of knee OA going from 0 to 4 by [CONTACT_18015], joint space 
narrowing, sclerosis and altered bone shapes68, 69.  
8.2.2 Phys ical examinations  
• A physical examination will include assessments of the cardiovascular, musculoskeletal and 
respi[INVESTIGATOR_2133], general appearance, thyroid gland and abdomen.  
• Body measurements (e.g. height and weight) will also be measured and recorded as 
specified in the flowchart.  
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
8.2.3 Vital signs  
• The method for measuring systolic and diastolic blood pressure needs to follow the standard 
clinical practice at site 
However, as a minimum:  
• Vital sign assessment should be preceded by [CONTACT_2669] [ADDRESS_16924] in a 
quiet setting without distractions (e.g. no use of television, cell phones).  
• Blood pressure and pulse rate measurements will be assesse d sitting with a completely 
automated device. Manual techniques must be used only if an automated device is not 
available.  
• Pulse rate will be measured in connection to the blood pressure measurements. Record the 
pulse rate for the last [ADDRESS_16925] 2 measurement.  
8.2.4 Clinical safety laboratory assessments  
Not applicable for this trial.  
8.3 Adverse events and serious adverse events  
The investigator is responsible for detecting, documenting, recording and following up on all the 
events listed below:  
• SAEs  
• Following AEs irrespective of seriousness  
o AEs leading to permanent discontinuation of trial product  
o AEs requiring invasive knee procedures  
o AEs with additional data collection:  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 42 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  43 of 90 
 
▪ medication error (including abuse/misuse of trial product)  
▪ acute pancreatitis  
o AEs of COVID -19a 
• Pregnancies and pregnancy -related AEs  
• Technical complaints  
a Suspected COVID -[ADDRESS_16926] (antigen or antibody) should be reported, if available.  
Note, that also events not allowed in accordance with the prot ocol e.g. bariatric surgery or knee 
replacement should, if they take place, be reported with both the procedure and medical condition 
specified.   
The definition of AEs and SAEs can be found in  Appendix 3 (Section 10.3), along with a 
description of  AEs requiring additional data collection.  
Some AEs require additional data collection on a specific event form. This always includes 
medication error, misuse and abuse of IMP. The relevant events are listed below in Table  8-1. 
Table  8-1 AEs requiring additional data collection (serious and non -serious AEs)   
Event type   AE requiring additional data collection  
Medication error*  X 
Misuse or abuse of trial product*  X 
Acute pancreatitis  X 
*Additional data for Misuse or abuse of trial product is reported on the medication error event form.  
A detailed description of the events mentioned in the above table can be found in  Appendix 3 
(Section 10.3). 
8.3.1 Time period and frequency for collecting AE and SAE information  
All events specified in Section 8.3 (for events related to pregnancy, see  Appendix 4 (Section 10.4) 
must be collected and  reported. The events must be collected from the first trial -related activity after 
obtaining informed consent until the end of trial visit, at the time points specified in the flowchart.  
Medical occurrences that take place or have onset prior to the time point from which AEs are 
collected will be recorded as concomitant illness/medical history. AE and SAE reporting timelines 
can be found in  Appendix 3 (Section 10.3). All SAEs must be recorded and reported to Novo 
Nordisk or designee within [ADDRESS_16927] has been 
discontinued from/completed the trial, and the investigator considers the event to be 
possibly/probably relate d to the trial product or related to trial participation, the investigator must 
promptly notify Novo Nordisk.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 43 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  44 of 90 
 
8.3.2 Method of detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in  Appendix 3 (Section 10.3). 
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and non -
leading verbal questioning of the subject is the preferred method to inquire about events.  
8.3.3 Follo w-up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs  should be followed until final outcome of the event or the 
subject is lost to follow -up as describ ed in Section 7.3. Further information on follow -up and final 
outcome of events is given in  Appendix 3 (Section 10.3).  
8.3.[ADDRESS_16928] under clinical investigation. Novo Nordisk 
will comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC, and investigators. This also includes suspected unexpected serious 
adverse reacti ons (S[LOCATION_003]R).  
An investigator who receives an investigator safety report describing a SAE or other specific safety 
information (e.g. summary or listing of SAEs) from Novo Nordisk will review and then file it along 
with the investigator's brochure and will n otify the IRB/IEC, if appropriate according to local 
requirements.  
8.3.[ADDRESS_16929] becomes pregnant, the investigator should inform Novo Nordisk within 14 
calendar days of learning of the pregnancy and should follow the procedures outlined in  Appendix 4 
(Section 10.4). 
8.3.6 Cardiovascular and death events  
Cardiovascular and death events will be handled and reported according to Section 8.3. 
8.3.7 Disease -related events and/or disease -related outcomes not qualifying as an AE or 
SAE  
Not applicable for this trial .  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 44 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16930]  
Not applicable for this trial .  
8.3.9 Technical complaints  
Technical complaints will be collected for all products listed on the technical complaint form.  
Instructions for reporting technical complaints can be found in  Appendix 5 (Section 10.5). 
In order for Novo Nordisk to perform a complete investigation of reported SAEs, Novo Nordisk 
might ask the investigator to complete a technical complaint form.   
8.4 Treatment of overdose  
• Overdoses of up to [ADDRESS_16931] commonly reported AE was nausea. All subjects recovered without 
complications.  
• There is no specific antidote for overdose with semaglutide. In the event of an overdose, 
appropriate supportive treatment should be initiated according to subject’s clinical signs and 
symptoms.  
Accidental overdose must be reported as a medication error. Intentional overdose must be reported 
as misuse and abuse, please refer to Section 8.3 and Appendix 3 (Section 10.3) for further details.  
In the event of an overdose, the investigator should closely monitor the subject for overdose -related 
AE/SAE. A prolonged period of observation and treatment may be necessary, taking into account 
the long half -life of semaglutide of approximately one week.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_18016] . 
For more information on overdose, also consult the current version of the investigator's brochure50 
and any updates hereof.  
8.5 Pharmacokinetics  
Not applicable for this trial .  
8.6 Pharmacodynamics  
Not applicable for this trial.  
8.7 Genetics  
Not applicable for this trial.  
8.8 Biomarkers  
Not applicable for this trial.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 45 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  46 of 90 
 
8.9 Immunogenicity assessments  
Not applicable for this trial.  
8.10 Health economics   
Not applicable for this trial.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 46 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  47 of 90 
 
9 Statistical considerations   
9.1 Statistical hypotheses  
The tests of superiority of semaglutide s.c. 2.4 mg once -weekly to semaglutide placebo for the two 
primary and all confirmatory secondary endpoints are performed using a fixed -sequence statisti cal 
strategy and a weighted Holm -Bonferroni procedure (with weights one). For a detailed specification 
of statistical hypotheses for the two primary endpoints see Section 9.4.2 . 
This strategy tests the endpoints using a predefined hierarchical order; first the two primary 
endpoints: body weight change (%) and change in WOMAC pain score are tested at the significance 
level of 5% where the alpha is split  between the two endpoints using 1% for body weight 
change   (%) and 4% for change in WOMAC pain score.  
If superiority is not confirmed for both endpoints, then the testing will stop. If the test of superiority 
for one of the two primary endpoints is signif icant, then the alpha can be recycled for the other 
primary endpoint, which will be tested at the 5% significance level. If both hypotheses are rejected 
and superiority is confirmed, then the confirmatory secondary endpoints (starting with ≥5% body 
weight reduction) will be tested at the 5% level. Testing for superiority of confirmatory secondary 
endpoints can proceed only after a statistically significant result (p -value < 5%) on the previous 
endpoint.  
9.2 Sample size determination   
The trial is designed with an effective power of 90% and 67% to detect differences on the two 
primary endpoints and confirmatory secondary endpoints, respectively. The effective power was 
calculated under the assumption of independence of endpoints by [CONTACT_18017] a conservative approach. The power calculations for 
continuous endpoints are based on a t -test on the mean difference assuming equal variances, 
whereas those for the categorical endpoints are bas ed on the Pearson chi -square test for two 
independent proportions.  
Assumptions for these calculations are presented in Table  9-1 and are based on findi ngs from 
NN9536 -4153 and NN9536 phase 3a program (STEP) as well as on relevant publications on body 
weight loss and knee OA outcome (using WOMAC). Two studies, Bliddal et al. and Christensen et 
al., found that weight loss treatment (average weight loss 7.5 % and 6.8% respectively) could lead to 
improvements in knee OA symptoms like pain and physical function (pain score: -8.4 (-10.4 vs -
2.0) with baseline score 38.4 (SD=21.1) and -5.4 (-11.4 vs -6.0) with baseline score 36.7 (SD=21.3) 
respectively; function score: -3.7 (-10.2 vs -6.5) with baseline score 39.2 (SD=21.4) and -9.9 (-14.9 
vs -5.0) with baseline value 37.4 (SD=21.8) respectively) in obese subjects (average BMI at 
baseline 35.6 and 35.9 respectively)28, 70. Aforementioned score improvements were found in 
treatment completers. Item responses were colle cted using the VAS format of the questionnaire. 
Bliddal et al. reported normalised sum of scores (range 0 -100) and Christensen et al. reported sum 
of scores, which were transformed to a 0 -100 range for comparison purposes. Consequently, a 
treatment differe nce for the pain score was assumed to be -9 (-11 vs -2) with SD=20; for the 
function score it was assumed to be -9 (-15 vs -6) with SD=19 if treated with semaglutide s.c. 2.4 
mg once -weekly vs semaglutide placebo for 68 weeks. Clement et al. identified a m inimum 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 47 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  48 of 90 
 
clinically important difference of 11 for pain and 9 for function and a minimum important change of 
21 for pain and 16 for function for improvement in WOMAC after total knee arthroplasty.71 
Although, it is planned to use the NRS fo rmat of the questionnaire in this trial, it is known that VAS 
and NRS are highly correlated (r>0.93) and that VAS derived assumptions for sample size 
calculation are adequate and can be translated to a setting where NRS is used72. It is planned that 
the WOMAC scores (derived from NRS responses) will be transformed to a 0 -100 range based on 
which the corresponding endpoints will be calculated.  
In relation to expected treatment effects it was assumed that 20% of subjects discontin ue 
permanently and 60% of these are retrieved at week 68. All subjects in the placebo arm are assumed 
to have same effect as subjects who complete the trial on placebo. Retrieved subjects in the 
semaglutide s.c. 2.[ADDRESS_16932] corresponding to half the 
treatment difference (compared to placebo) of subjects who complete the trial on semaglutide s.c. 
2.[ADDRESS_16933] cor responding to placebo.  
Under these assumptions and a 2:[ADDRESS_16934] 90% for 
change in WOMAC pain score is obtained with 375 subjects randomised to either receive 
semaglutide s.c. 2.4 mg once -weekly (250) or placebo (125).  
Table  9-1 Assumptions, marginal power and effective power for each endpoint in the 
hierarchical testing procedure given an anticipated number of 375 randomised 
subjects  
Order  Endpoint  Assumed mean (±SD) or 
proportion for completers  Expected 
mean ( ±SD) 
or 
proportion  Expected 
difference 
or 
proportion 
ratio Marginal 
power 
(%) Two -sided 
significance 
level (%) *  Effective 
power 
(%) Semaglutide 
s.c. 2.4 mg 
once -weekly  Semaglutide  
placebo  Semaglutide 
s.c. 2.4 mg 
once -weekly  
1 % body 
weight 
change #  14.0 (±10)  3.0 (±10)  12.5 ( ±11) 9.5% -
points  >99 1 99 
1 WOMAC 
pain 
change #  11.0 (±20)  2.0 (±20)  9.7 (±21)  7.7 score -
points  90 4 90 
2 5% 
responders  82% 42% 76% 1.8 >99 5 90 
3 10% 
responders  66% 24% 60% 2.5 >99 5 90 
4 WOMAC 
function 
change # 15.0 ( ±19) 6.0 (±19) 13.7 ( ±20) 7.7 score -
points  94 5 84 
5 SF-36 
physical 
functioning 
change  6.0 (±10) 2.0 (±10) 5.4 (±11) 3.4 score -
points  80 5 67 
SD: Standard deviation; WOMAC: Western Ontario McMasters Osteoarthritis Index ; SF -36: Short Form (36) Health 
Survey.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 48 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  49 of 90 
 
*Significance level for confirmatory secondary endpoints reflects local alpha if all superiority hypotheses for endpoints 
higher in the statistical hierarchy were rejected  
# Shown as a positive number  
 
As currently there are no NN trials utilizing WOMAC, see Table 9-[ADDRESS_16935] 
deviation.  
 
Table 9-2 Marginal power for WOMAC pain change (shown as a positive number) for 
alternative sample size, mean difference or standard deviation  
Sample size  Expected mean 
for semaglutide  
placebo  Expected mean 
for semaglutide 
s.c. 2.4 mg once -
weekly  Expected 
difference  Common SD  Marginal 
power (%)  
Main scenario  
375 2 9.7 7.7 21 0.900  
Varying sample size  
285 2 9.7 7.7 21 0.803  
303 2 9.7 7.7 21 0.828  
324 2 9.7 7.7 21 0.853  
348 2 9.7 7.7 21 0.877  
375 2 9.7 7.7 21 0.900  
411 2 9.7 7.7 21 0.925  
462 2 9.7 7.7 21 0.951  
543 2 9.7 7.7 21 0.975  
888 2 9.7 7.7 21 >.999  
Varying mean difference  
375 2 5 3 21 0.226  
375 2 6 4 21 0.375  
375 2 7 5 21 0.545  
375 2 8 6 21 0.708  
375 2 9 7 21 0.837  
375 2 10 8 21 0.921  
375 2 11 9 21 0.968  
375 2 12 10 21 0.989  
375 2 13 11 21 0.997  
375 2 14 12 21 >.999  
375 2 15 13 21 >.[ADDRESS_16936] deviation  
375 2 9.7 7.7 10 >.999  
375 2 9.7 7.7 11 >.999  
375 2 9.7 7.7 12 >.999  
375 2 9.7 7.7 13 >.999  
375 2 9.7 7.7 14 0.998  
375 2 9.7 7.7 15 0.996  
375 2 9.7 7.7 16 0.990  
375 2 9.7 7.7 17 0.981  
375 2 9.7 7.7 18 0.967  
375 2 9.7 7.7 19 0.949  
375 2 9.7 7.7 20 0.927  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 49 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  50 of 90 
 
375 2 9.7 7.7 21 0.900  
375 2 9.7 7.7 22 0.871  
375 2 9.7 7.7 23 0.840  
375 2 9.7 7.7 24 0.807  
375 2 9.7 7.7 25 0.773  
375 2 9.7 7.7 26 0.740  
375 2 9.7 7.7 27 0.706  
375 2 9.7 7.7 28 0.673  
375 2 9.7 7.7 29 0.642  
375 2 9.7 7.7 30 0.611  
SD: Standard deviation.  
 
All above outlined sample size and power considerations are for the primary estimand for primary 
endpoints or the secondary estimand for confirmatory secondary endpoints (treatment policy 
strategy). It is assumed that up to 20% of subjects discontinue permanently and 60% of these are 
retrieved at  week 68, which amounts to 8% expected missing data at week 68. Based on NN9536 
STEP 1 trial 8.8% missing in -trial data was observed after 68 weeks for the primary estimand. Any 
superiority conclusions will be based on the primary or secondary estimand.  
 
For the additional estimand (hypothetical strategy) however, data from retrieved subjects are not 
used. Hence, it is expected that up to 20% of data will be missing at week 68. Based on NN9536 
STEP 1 trial 20.6% missing on -treatment data was observed after  68 weeks for the additional 
estimand. This included missing data not only due to treatment discontinuation, but also due to 
initiation of other anti -obesity therapi[INVESTIGATOR_014] (<1%). For trial NN9536 4578 slightly higher missing on -
treatment data is expected due t o subjects initiating other knee OA interventions (<3%) and not 
complying with the washout period (<10%). In NN9536 STEP [ADDRESS_16937] deviation was slight ly 
lower for the additional estimand (using on -treatment data) than for the primary estimand (using in -
trial data).  
9.3 Populations for analyses  
Two analysis sets are defined:  
The full analysis set (FAS)  includes all randomised subjects according to the intent ion-to-treat 
principle. The subjects in the FAS contribute to the evaluation as randomised.  
The safety analysis set (SAS)  includes all randomised subjects exposed to at least one dose of 
randomised treatment. The subjects in the SAS contribute to the evalu ation as treated.  
Any observation excluded from the analysis database will be documented before database lock with 
the reason for exclusion provided. Efficacy endpoints will be analysed using the FAS; safety 
endpoints will be analysed using the SAS.  
Two ob servation periods are defined for each subject:  
In-trial: The in-trial period  is defined as the uninterrupted time interval from date of randomisation 
to date of last contact [CONTACT_18018].  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 50 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  51 of 90 
 
On-treatment (with trial product): A time -point is considered as  “on-treatment” if any dose of trial 
product has been administered within the prior 2 weeks (14 days). The on-treatment period is 
defined as all times which are considered on -treatment.  
In general, the on-treatment period will therefore be from the date of  first trial product 
administration to date of last trial product administration excluding potential off -treatment time 
intervals triggered by [CONTACT_18019].  
For the evaluation of AEs, the lag time for each on -treatment time interva l is 7 weeks (49 days).  
The in -trial and on -treatment periods define the patient years of observation (PYO) and patient 
years of exposure (PYE), respectively, as the total time duration in the periods.  
9.4 Statistical analyses  
9.4.1 General considerations  
A statisti cal analysis plan (SAP) will be written, including a more technical and detailed elaboration 
of the statistical analyses. The SAP will be finalised before breaking the blind to treatment 
assignment.  
The last available and eligible observation at or before randomisation is used as the baseline value. 
If no assessments are available, the mean value at randomisation across all subjects is used as the  
baseline value.  
9.4.2 Primary endpoint (s) 
The primary endpoints are change in body weight (%) and change in WOMAC pai n score from 
baseline (week 0) to end -of-treatment (week 68) as listed in Section 3. 
Change from baseline to week 68 in body weight (%) is defined as  
% body weight change = (body weight at week 68 – body weight at baseline)
body weight at baseline ×100.  
Change from baseline to week 68 in WOMAC pain score is defined as  
WOMAC pain score change = WOMAC pain score at week 68 – WOMAC pain score at baseline.  
All tests are tests of superiority of semaglutide s.c. 2.4 mg once -weekly to semaglutide placebo.  
Let μ semaglutide  and μ semaglutide placebo  denote the true mean of % body weight change or WOMAC pain 
score change for semaglutide s.c. 2.4 mg once -weekly and s emaglutide placebo, respectively. The 
null and alternative hypotheses tested are  
𝐻0: 𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒 ≥𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒  𝑝𝑙𝑎𝑐𝑒𝑏𝑜  𝑣𝑠
𝐻𝐴:𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒 <𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒  𝑝𝑙𝑎𝑐𝑒𝑏𝑜 . 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 51 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  52 of 90 
 
The null hypotheses will be rejected and superiority claimed, if the upper limit of the estimated two -
sided 95% CI is below 0.  
Analyses addressing the primary estimand  
The following statistical analyses and imputation methods are designed to address the primary 
estimand.  
The analysis  model for change in body weight (%) and change in WOMAC pain score will be a 
linear regression (ANCOVA) with randomised treatment as factor and either baseline body weight 
(kg) or baseline WOMAC pain score as covariate. The estimated treatment difference between 
semaglutide s.c. 2.4 mg once -weekly and semaglutide placebo will be reported together with the 
associated two -sided 95% confidence interval (CI) and corresponding p -value.  
All available data at week [ADDRESS_16938] available observation 
during the on -treatment period (LAO -OT) as well as by [CONTACT_18020], baselin e BMI and baseline body 
weight /WOMAC pain score  into account. Missing measurements at week 68 for subjects on 
randomised treatment (at week 68) are imputed by [CONTACT_18021] 
68 from subjects on randomised treatment in the rele vant randomised treatment arms. Details of the 
multiple imputation approach are provided in the SAP.  
Analysis addressing the additional estimand  
The additional estimand for change in body weight (%) and change in WOMAC pain score will be 
assessed using a mixed model for repeated measurements (MMRM) approach.  
Week [ADDRESS_16939] discontinuing of randomised treatment, the date of initiating other 
anti-obesity therapi[INVESTIGATOR_014] (weight management drugs or bariatric surg ery) or other knee OA 
interventions (joint replacement or steroid injections) will be used as latest date for using 
assessments in this MMRM. Additionally, for the MMRM analysing change in WOMAC pain 
score, assessments from subjects incompliant with the wa shout period for pain medication will not 
be used. The MMRM will be fitted using the change (% body weight change or change in WOMAC 
pain score) and the same factor and covariate as for the primary analysis all nested within visit. An 
unstructured covarian ce matrix for measurements within the same subject will be employed, 
assuming that measurements for different subjects are independent.  
9.4.3 Secondary endpoints  
[IP_ADDRESS]  Confirmatory secondary endpoints  
The confirmatory secondary endpoints are listed in Section 3. 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 52 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16940] as the primary endpoints addressing the primary estimand.  
The statistical model for continuous confirmatory secondary endpoints will be the same linea r 
regression as for the primary endpoints (ANCOVA) with treatment as a factor and the baseline 
value of the endpoint as covariate. The statistical model for confirmatory body weight responder 
endpoints is a logistic regression using randomised treatment as  a factor and baseline body weight 
(kg) as covariate. The estimated odds ratio (OR) between semaglutide s.c. 2.4 mg once -weekly and 
semaglutide placebo will be reported together with the associated two -sided 95% confidence 
interval and corresponding p -value.  
The imputation approach is the same multiple imputation using retrieved subjects as described in 
Section 9.4.2  and taking the baseline value of t he endpoint into account.  
Analyses addressing the additional estimand  
The confirmatory secondary endpoint change in WOMAC physical function score addressing the 
additional estimand will be analysed using the same MMRM as described for the primary endpoint  
change in WOMAC pain score addressing the additional estimand with randomised treatment as a 
factor and the baseline value of the endpoint as covariate.  
The confirmatory body weight responder endpoints addressing the additional estimand will be 
analysed using the same MMRM described for the primary endpoint change in body weight (%) 
addressing the additional estimand except that body weight (kg) will be used as response variable in 
the model. For subjects with missing body weight at week 68, individual va lues for body weight 
will be predicted from the MMRM and used to classify each subject as 5% or 10% responder or not. 
This classification will then be analysed using a logistic regression model with randomised 
treatment as a factor and baseline body weight  (kg) as covariate.  
[IP_ADDRESS]  Supportive secondary endpoints  
For details on analyses of supportive secondary endpoints, please see the SAP.  
9.4.4 Exploratory endpoints  
For details on analyses of exploratory endpoints, please see the SAP.  
9.4.5 Other safety analyses  
For other safety analyse(s), please see the SAP.  
9.4.6 Other analyse(s)   
Not applicable for this trial.  
[IP_ADDRESS]  Pharmacokinetic and/or pharmacodynamic modelling  
Not applicable for this trial.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 53 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  54 of 90 
 
9.5 Interim analyses  
Not applicable for this trial.  
9.6 Data monitoring committee  
Not applicable for this trial.  
9.7 Reporting of the main part of the trial  
Not applicable for this trial.   
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 54 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  55 of 90 
 
10 Supporting documentation and operational considerations  
10.1 Appendix 1: Regulatory, ethical, and trial oversight considerations  
10.1.1  Regulatory and ethical consid erations  
• This trial will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki74 and applicable ICH Good Clinical Practice (GCP) Guideline75 
• Applicable laws and regulations  
• The protocol, informed consent form, IB (as applicable) and other relevant documents (e.g. 
advertisements) must be submitted to an IRB/IEC and reviewed and approved by [CONTACT_5040]/IEC before the trial is initiated.  
• Regulatory authorities will receive the clinical trial application, protocol amendments, 
reports on SAEs, and the clinical trial report (CTR) according to national requir ements.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate 
safety hazard to trial subjects.  
• Before a site is allowed to start screen ing subjects, written notification from Novo Nordisk 
must be received.  
• The investigator will be responsible for:  
• providing written summaries of the status of the trial annually or more frequently in 
accordance with the requirements, policies, and procedure s established by [CONTACT_1201]/IEC 
and/or regulatory authorities  
• notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC 
procedures  
• providing oversight of the conduct of the trial at the site and adherence to requirements of 
ICH guidelines, the IRB/IEC, and all other applicable local regulations  
• ensuring submission of the CTR synopsis to the IRB/IEC  
• reporting any potential serious breaches to the sponsor immediately after discovery  
10.1.2  Financial disclosure  
Investigators and sub-investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Inves tigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial.  
Verification under disclosures per Code of Federal Regulations (CFR) of Financial Conflict of 
Interest.  
10.1.3  Informed consent process  
• The investigator or his/her representative will explain the nature of the trial to the subject 
and answer all questions regarding the trial.  This includes the use of an impartial witness 
where required according to local requirements.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 55 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  56 of 90 
 
• The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.   
• Subjects must be informed that their participation is voluntary.  
• Subjects must be informed about their privacy rights.  
• Subjects will be  required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines75, Declaration of Helsinki74 and the 
IRB/IEC or site.  
• The medical record must include a statement that written informed consent was obtained 
before any trial -related activity and the date when the written consent was obtained. The 
authorised person obtaining the informed consent must also sign and date the informed 
consent form before any trial -related activity.  
• The responsibility of seeking informed consent must  remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local 
requirements.  
• Subjects must be re -consented to the most current version of the informed consent form (s) 
during their partici pation in the trial.  
• A copy of the informed consent form (s) must be provided to the subject .  
10.1.[ADDRESS_16941] may receive a “welcome to the trial letter” and a “thank you for your participation letter” 
after completion of the trial. Further, the subject may receive other written information during the 
trial.  
Different initiatives for sub ject retention will be implemented throughout this trial. Site retention 
activities may include cooking classes, group meetings and others. Materials and items will be 
supplied if locally acceptable. The retention items will be relevant for the subjects’ p articipation in 
the trial and/or their obesity and will not exceed local fair market value.  
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].  
The initiatives for subject retention must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].  
10.1.5   Data protection  
• Subjects will be assigned a [ADDRESS_16942] are transferred to Novo Nordisk.  
• The subject and any biological material obtained from the subject will be identified by 
[CONTACT_18022], visit number and trial ID. Appropriate measures such as encryption or 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 56 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16943] the identity of subjec ts as required 
by [CONTACT_5737], regional and national requirements.   
• The subject must be informed about his/her privacy rights, including that his/her personal 
trial-related data will be used by [CONTACT_18023]. 
The discl osure of the data must also be explained to the subject.   
• The subject must be informed that his/her medical records may be examined by [CONTACT_18024], by [CONTACT_6667]/IEC members, 
and by [CONTACT_6668].  
10.1.6  Committees structure  
[IP_ADDRESS]  Novo Nordisk safety committee  
Novo Nordisk will perform ongoing safety surveillance. If new safety signals are identified, these 
will be evaluated by [CONTACT_18025].  The safety committee may recommend 
unblinding of any data for further analysis, and in this case an internal trial independent ad hoc 
group will be established in order to maintain the blinding of the trial personnel . 
[IP_ADDRESS]  Trial safety group  
Not applicable for this trial.  
[IP_ADDRESS]  Data monitori ng committee  
Not applicable for this trial.  
[IP_ADDRESS]  Event adjudication committee  
Not applicable for this trial.  
10.1.7  Dissemination of clinical trial data  
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk -trials.com. It will also 
be disclo sed according to other applicable requirements, such as those of the International 
Committee of Medical Journal Editors (ICMJE)76, the Food and Drug Administration Amendment 
Act (FDAAA)77, European Commission Requirements1, 78, [ADDRESS_16944] at 
these web sites, Novo Nordisk may disclose t he investigator’s contact [CONTACT_18026]. As a 
result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations.  
The primary completion date is the last assessment of the prim ary endpoint, and is for this trial Last 
Subject First Treatment + 68 weeks corresponding to ‘end of treatment’ visit  (V13). If the last 
subject is withdrawn early, the PCD is considered the date when the last subject would have 
completed ‘end of treatment ’ visit. The PCD determines the deadline for results disclosure at 
clinicaltrials.gov according to FDAAA.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 57 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  58 of 90 
 
10.1.8  Data quality assurance  
[IP_ADDRESS]  Case report forms  
• Novo Nordisk or designee is responsible for the data management of this trial including 
quality checking of t he data.  
• All subject data relating to the trial will be recorded on electronic CRFs unless transmitted 
electronically to Novo Nordisk or designee (e.g. laboratory data). The investigator is 
responsible for verifying that data entries are accurate and corre ct by [CONTACT_18027].   
• The following will be provided as paper CRFs:  
o Pregnancy forms (Maternal forms 1A, 1B and 2 and Paternal form)  
• The following will be provided as paper CRFs to be used when access to the CRF is revoked 
or the CRF is temporarily unavailable:  
o AE forms   
o Safety information forms  
o Technical complaint forms (also to be used to report complaints on trial product not 
yet allocated to a subject)  
• Corrections to the CRF data may be made by [CONTACT_18028]’s delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the 
old and the new data, identification of the person entering the data, date and time of the 
entry and reason for the correction. If correctio ns are made by [CONTACT_093]’s delegated 
staff after the date when the investigator signed the CRF, the CRF must be signed and dated 
again by [CONTACT_093].  
• The investigator must ensure that data is recorded in the CRF as soon as possible, preferably  
within 5 working days after the visit. Once data has been entered, it will be available to 
Novo Nordisk for data verification and validation purposes .  
[IP_ADDRESS]  Monitoring  
• The investigator must permit trial -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents (original 
documents, data and records). Direct access includes permission to examine, analyse, verify 
and reproduce any record(s) and report(s) that are important to the evalu ation of the trial. If 
the electronic medical record does not have a visible audit trail, the investigator must 
provide the monitor with signed and dated printouts. In addition, the relevant site staff 
should be available for discussions at monitoring visi ts and between monitoring visits (e.g. 
by [CONTACT_756]).   
• Trial monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_18029], complete and verifiable from source 
documents; that the  safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is 
being conducted in accordance with the currently approved protocol and any other trial 
agreements , ICH GCP, and all applicable regulatory requirements.  
• Monitoring will be conducted using a risk -based approach including risk assessment, 
monitoring plans, centralised monitoring (remote assessment of data by [CONTACT_3454]) and 
visits to sites.   
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 58 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  59 of 90 
 
• Monitors w ill review the subject’s medical records and other source data, e.g. PROs , to 
ensure consistency and/or identify omissions compared to the CRF.   
[IP_ADDRESS]  Protocol compliance  
Deviations from the protocol should be avoided. If deviations do occur, the investigator mu st 
inform the monitor without delay and the implications of the deviation must be reviewed and 
discussed.  
Deviations must be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which c orrections are not possible, can be 
acknowledged and confirmed via edit checks in the CRF or via listings from the trial database.   
10.1.9  Source documents . 
• All data entered in the eCRF must be verifiable in source documentation other than the CRF  
• For ePROs, data  in the service providers’ database is considered source data.  
• Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the site.  
• Data entered in the eCRF that ar e transcribed from source documents must be consistent 
with the source documents, or the discrepancies must be explained. The investigator may 
need to request previous medical records or transfer records. Also, current medical records 
must be available.   
• It must be possible to verify subject’s medical history in source documents, such as subject’s 
medical record   
• The investigator must document any attempt to obtain external medical information by 
[CONTACT_18031](s) when information was requested, and who wa s contact[INVESTIGATOR_530].  
• Definition of what constitutes source data can be found in a source document agreement at 
each site. There will only be one source document defined at any time for any data element.  
10.1.10  Retention of clinical trial documentation  
• Records and documen ts, including signed informed consent forms, pertaining to the conduct 
of this trial must be retained by [CONTACT_1732] 15 years after end of trial unless local 
regulations or institutional policies require a longer retention period.  This also applie s for 
services outsourced to an external facility by [CONTACT_093].  No records may be destroyed 
during the retention period without the written approval of Novo Nordisk. No records may 
be transferred to another location or party without written notifica tion to Novo Nordisk.   
• The investigator must be able to access his/her trial documents without involving Novo 
Nordisk in any way. If applicable, electronic CRF (eCRF) and other subject data will be 
provided in an electronic readable format to the investiga tor before access is revoked to the 
systems and/or electronic devices supplied by [CONTACT_3454]. Site -specific CRFs and other 
subject data (in an electronic readable format or as paper copi[INVESTIGATOR_17951]) must be retained 
by [CONTACT_779]. A copy of all data will be stored by [CONTACT_3454].  
• Subject’s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 59 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16945] 
inform the subjects promptly and ensure appropriate therapy and follow -up. The investigator and/or 
Novo Nordisk must also promptly inform  the regulatory authorities and IRBs/IECs and provide a 
detailed written explanation.  
Sites will be closed upon trial completion. A site is considered closed when all required documents 
and trial supplies have been collected and a site closure visit has be en performed.  
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a site by [CONTACT_18032]:  
• failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, Novo Nordisk procedures or GCP guidelines  
• inadequate recruitment of subjects by [CONTACT_093]  
• discontinuation of further trial product development.  
10.1.[ADDRESS_16946] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the site. If any tasks are delegated, th e investigator must 
maintain a log of appropriately qualified persons to whom he/she has delegated specified trial -
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the  trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well -being of the subjects.   
A qualified physician, who is an investigator or a sub investigator for the trial, must be responsible  
for all trial -related medical decisions.   
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification 
code list must be kept in a secure locked facility so that no unauthorized persons can get access to 
the data.   
The investigator will take all necessary technical and organ isational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to p rovide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.  
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subject s to a specific qualified physician who will be readily available to subjects during that time.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 60 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  61 of 90 
 
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation  with Novo Nordisk.   
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).  
10.1.[ADDRESS_16947] liability for its products, and liability as assumed under the special  
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.   
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the trial or by [CONTACT_18033].  Novo Nordisk may pay additional costs incurred in relation to assessments relevant for 
following the safety of the subject. Investigator must contact [CONTACT_18034] a case by [CONTACT_18035] w hether the costs will be covered.  
Novo Nordisk accepts liability in accordance with: Please refer to  Appendix 7 (Section 10.7). 
10.1.[ADDRESS_16948], if deemed necessary by [CONTACT_3454]. 
Provided that  certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this trial to researchers who require access for research projects studying the same 
disease and/or trial product studied in this trial.  
Novo Nordisk may publis h on its clinical trials website a redacted CTR for this trial.  
One (or two) investigators will be appointed by [CONTACT_18036] 
(signatory investigator) on behalf of all participating investigators.   
[IP_ADDRESS]  Communication of results  
Novo No rdisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes publication of a manuscript in a peer -reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disc losure by [CONTACT_11174].   
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are re ached, for example when the CTR is available. This includes the 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 61 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  62 of 90 
 
right not to release the results of interim analyses, because the release of such information may 
influence the results of the entire trial.  
At the end of the trial, one or more scientific pub lications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_16949] intellectual property.  
In all cases, the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_17952].  
[IP_ADDRESS]  Authorship  
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, analysis or interpretation of data to report the results in o ne 
or more publications.  
Authorship of publications should be in accordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by [CONTACT_18037].80 
All authors will be provi ded with the relevant statistical tables, figures, and reports needed to 
evaluate the planned publication.   
Where required by [CONTACT_18038], the investigator from each site will be named in an 
acknowledgement or in the supplementary material, as specified by  [CONTACT_18038].   
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s)  
For a multicentre clinical trial, analyses based on single -site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare profess ionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Pub lication Practice, such individual reports should 
not precede the primary manuscript and should always reference the primary manuscript of the trial.  
[IP_ADDRESS]  Investigator access to data and review of results  
As owner of the trial database, Novo Nordisk has the dis cretion to determine who will have access 
to the database.  
Individual investigators will have their own research subjects' data and will be provided with the 
randomisation code after results are available.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 62 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  63 of 90 
 
10.2 Appendix 2: Clinical laboratory tests  
• The tests detailed in Table  10-1 will be performed by [CONTACT_12082]  
• Additional tests may be performed at any time during the trial as determined necessary by 
[CONTACT_11006]. If additional laboratory sampling is needed, 
e.g. to follow up on AEs, this must be done at a local laboratory.  
• The investigator  must review all laboratory results for concomitant illnesses an d AEs.  
Table  10-1 Protocol -required laboratory assessments  
Laboratory assessments  Parameters  
Glucose metabolism1 • HbA1 c  
Pregnancy Testing  • Highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)2 
Notes:  
1For screening purposes only  
2Local urine testing will be standard unless serum testing is required by [CONTACT_18039]/IEC.  
HbA1 c; glycated haemoglobin, IRB; institutional review board, IEC; independent ethics committee
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 63 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  64 of 90 
 
10.3 Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, 
follow -up, and reporting  
10.3.[ADDRESS_16950] that is temporally associated 
with the use of an IMP, whether or not considered related to the IMP.  
An AE can therefore be any unfavourable and unintended sign, including an abnormal laboratory 
finding, symptom or disease (new or exacerbated) temporally associated with the use of an IM P. 
 
Events meeting  the AE definition  
• Any abnormal laboratory test results or safety assessments considered clinically significant in 
the medical and scientific judgment of the investigator, including events that have worsened 
from prior to the time point  from which AEs are collected  
• Conditions detected or diagnosed after IMP administration even though it may have been 
present prior to the time point from which AEs are collected  
• Exacerbation/worsening of a chronic or intermittent condition including eithe r an increase in 
frequency and/or intensity of the condition  
• Signs, symptoms or the clinical sequelae of a suspected drug -drug interaction  
• Signs, symptoms or the clinical sequelae of a suspected overdose of IMP regardless of intent  
• Obesity -related surgica l procedures, total knee replacements and knee arthroscopy  
A "lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as 
an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, 
symptoms and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE 
if they fulfil the definition . 
Events NOT  meeting the AE definition  
• Conditions present prior to the time point from which AEs are collected and anticipated day -
to-day fluctuations of these conditions, including those identified during screening or other 
trial procedures performed before exposure to IMP.  
• Note: Conditions p resent or occurring prior to the time point from which AEs are collected 
should be recorded as concomitant illness/medical history.  
• Medical or surgical procedures (e.g. endoscopy, appendectomy). The condition that leads to 
the procedure is the AE. · Except ions include; obesity -related surgical procedures, total knee 
replacements and knee arthroscopy. In these cases both the surgical procedure and the 
condition that leads to the procedure should be reported as AEs.   
• Medical or surgical procedures not precede d by [CONTACT_18040] a known condition 
(exceptions are obesity -related surgical procedures, which  for this trial should be reported as 
individual AE's).  
10.3.[ADDRESS_16951] one of the following criteria:  
a. Re sults in death  
b. Is life -threatening  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 64 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  65 of 90 
 
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_15574]  
• Hospi[INVESTIGATOR_17953]/or treatment that would not  have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_17954]. If a 
complication prolongs hospi[INVESTIGATOR_17955], the event is 
serious. When in doubt as to  whether “hospi[INVESTIGATOR_11956]” occurred or was necessary, the AE 
should be considered serious.  
• Hospi[INVESTIGATOR_17956] (e.g. elective medical or surgical procedures) of a 
condition that was present prior to the time point from which AEs are coll ected, and that did 
not worsen, is not considered an AE.  
•   Note:  
• Hospi[INVESTIGATOR_17957], trial -related, social and convenience reasons do not 
constitute AEs and should therefore not be reported as AEs or SAEs.   
• Hospi[INVESTIGATOR_17958], planned before trial inclusion, are not 
considered AEs or SAEs.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  
• This definition is not intended to include experience of relatively minor medical significance, 
such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental 
trauma (e.g. sprained ankle), which may interfere with or prev ent everyday life functions but 
do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Important medical event:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations. This includes important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_17959]. These events should usually be considered serious and reported 
as SAEs using the important medical event criterion.  
• The following adverse events must always be reported as SAEs using the important medical 
event criterion if no oth er seriousness criteria are applicable:  
• Suspi[INVESTIGATOR_17960]  
• Risk of liver injury defined as alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) >3 x UNL and total bilirubin >2 x UNL where no alternativ e 
aetiology exists (Hy's law)  
 
10.3.3  Description of AEs requiring additional data collection  
Description of AEs requiring additional data collection (on specific event form)  
Adverse events requiring additional data collection  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 65 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16952] (see Table  8-1). The selection of these events is based 
on the non -clinical and clinical data with semaglutide, knowledge from the GLP -1 RA drug class 
as well as regulatory requirements.  
Acute pancreatitis  
Diagnosis of acute pancreatitis requires two of the following t hree features:  
1. abdominal pain consistent with acute pancreatitis (onset of a persistent, severe, epi[INVESTIGATOR_17961])  
2. serum lipase activity (and/or amylase activity) at least three times greater than the upper 
limit of normal  
3. charac teristic findings of acute pancreatitis on imaging.  
Medication error  
A medication error is an unintended failure in the IMP treatment process that leads to, or has the 
potential to lead to, harm to the subject, such as:   
• administration of wrong drug  
Note:  Use of wrong DUN is not considered a medication error unless it results in 
administration of wrong drug.  
• wrong route of administration, such as intramuscular instead of subcutaneous  
• accidental administration of  higher dose than intended. The administered dose must deviate 
from the intended dose to an extent where clinical consequences for the trial subject were 
likely to happen as judged by [CONTACT_093], although they did not necessarily occur.  
• missed doses or drug pauses are not to be rep orted as a medication error.  
Misuse and abuse   
• Situations where the IMP is intentionally and inappropriately used not in accordance with the 
protocol (e.g. overdose to maximise effect)  
• Persistent or sporadic, intentional excessive use of an IMP which is accompanied by [CONTACT_18041] (e.g. overdose with the intention to cause harm)  
Medication error, misuse and abuse must always be reported as an AE (e.g. accidental overdose, 
intentional overdose or other) on a separate AE form, a nd a medication error, misuse and abuse 
form must be completed. In case of a medication error and/or misuse and abuse resulting in a 
clinical consequence (e.g. hypoglycaemia or other), this must be reported on an additional AE 
form.  
 
10.3.4  Recording and follow -up of AE and/or SAE  
AE and SAE recording  
• The investigator will record all relevant AE/SAE information in the CRF.  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such case s, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
• SAEs and  AEs listed in Section 8.3 and AEs/SAEs in connection with pregnancies, must be 
recorded by [CONTACT_18042]. The investigator will attempt to establish a diagnosis 
of the event based on signs, symptoms, and/or other clinical information. In such cases, the 
diagnosis (no t the individual signs/symptoms) will be documented as the AE/SAE .  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 66 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  67 of 90 
 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospi[INVESTIGATOR_1088], laboratory and diagnostics reports) related to the 
event.  
• There may be instances when copi[INVESTIGATOR_14168] (e.g. medical records) for certain 
cases are requested by [CONTACT_3454]. In such cases, all subject identifiers, with the exception 
of the subject number, will be redacted on the copi[INVESTIGATOR_17962].  
• For all non -serious AEs, the applicable forms should be signed when the event is resolved or 
at the end of the trial at the latest. For sign -off of SAE -related forms, refer to “AE and SAE 
reporting via paper CRF” lat er in this section.  
• Novo Nordisk products used as concomitant medication: if an AE is considered to have a 
causal relationship with a Novo Nordisk marketed product used as  concomitant medication in 
the trial, it is important that the suspected relationship  is reported to Novo Nordisk, e.g. in the 
alternative aetiology section on the safety information form. Novo Nordisk may need to 
report this adverse event to relevant regulatory authorities.  
 
Assessment of severity  
The investigator will assess severity f or each event reported during the trial and assign it to one of 
the following categories:   
• Mild : An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and not 
interfering with everyday activities.  
• Moderate : An event that causes suffi cient discomfort and interferes with normal everyday 
activities.  
• Severe : An event that prevents normal everyday activities.   
Note: An AE that is assessed as severe should not be confused with a SAE. Both AEs and 
SAEs can be assessed as severe.  
 
Assessment of causality  
• The investigator is obligated to assess the relationship between IMP and the occurrence of 
each AE/SAE.  
• Relationship between an AE/SAE and the relevant IMP(s) should be assessed as:   
• Probable - Good reason and sufficient documentation to assume a causal relationship.  
• Possible - A causal relationship is conceivable and cannot be dismissed.  
• Unlikely - The event is most likely related to aetiology other than the IMP.  
• Alternative aetiology, such as underlying disease(s), conco mitant medication, and other risk 
factors, as well as the temporal relationship of the event to IMP administration, will be 
considered and investigated.  
• The investigator will also consult the IB in his/her assessment.  
• For each AE/SAE, the investigator must document in the medical records that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred, and the investigator has minimal 
information to include in the initial report. Howev er, it is important that the investigator 
always makes an assessment of causality for every event before the initial transmission 
of the SAE data.  
• The investigator may change his/her opi[INVESTIGATOR_17963], in light of follow -up information, 
and update the c ausality assessment in the CRF.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 67 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16953] appropriate outcome:  
• Recovered/resolved:  The subject has fully re covered, or by [CONTACT_18043]  
• Recovering/resolving:  The condition is improving, and the subject is expected to recover 
from the event. This term may be applicable in case s of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE).   
• Note: For SAEs, this term is only applicable if the subject has completed the follow -up period 
and is expected to recover.  
• Recovered/resolved with sequelae:  The subject has recovered from the condition but with 
lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE 
criterion, the AE must be reported as an SAE.  
• Not recovered/not resolved:  The condition of the subjec t has not improved, and the 
symptoms are unchanged, or the outcome is not known.  
Note: This term may be applicable in cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE).   
• Fatal:  This term is only applica ble if the subject died from a condition related to the reported 
AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as 
“recovered/resolved”, “recovering/resolving”, “recovered/resolved with sequelae” or “not 
recovered/not  resolved”. An AE with a fatal outcome must be reported as an SAE.  
• Unknown:  This term is only applicable if the subject is lost to follow -up. 
 
Follow -up of AE and SAE  
The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_18044]/or causality of the AE or SAE as fully as possible (e.g. severe hypersensitivity reactions). 
This may include additional laboratory tests (e. g. skin prick test) or investigations, 
histopathological examinations, or consultation with other health care professionals.  
If a subject dies during participation in the trial or during a recognised follow -up period, the 
investigator should provide Novo N ordisk with a copy of autopsy report including 
histopathology.  
New or updated information will be recorded in the CRF.  
 
10.3.5  Reporting of SAEs  
SAE reporting via electronic CRF  
• Relevant forms (AE form, safety information form and specific event forms) must be 
completed in the CRF.  
• For reporting and sign -off timelines, see Figure  10-1 below.  
• If the CRF is unavailable for more than 24 hours, then the site will use the paper AE form, 
and if the CRF is unavailable for more than 5 calendar days, then the site will use the paper 
safety information form (see box below).  
• The site will enter the SAE data into the CRF as soon as it becomes available.  
• After the trial is completed, the trial database will be locked, and the CRF will be 
decommissioned to prevent the entry of new data or changes to existing data. If a site receives 
a report o f a new SAE from a subject or receives updated data on a previously reported SAE 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 68 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  69 of 90 
 
after CRF decommission, then the site can report this information on a paper AE and safety 
information form (see box below) or to Novo Nordisk  by [CONTACT_756].  
 
AE and SAE reporting via paper CRF  
• Relevant CRF forms (AE and safety information form)  must be forwarded to Novo Nordisk 
in accordance with  Section 10.1.5 . 
• For SAEs, initial notification via telephone is acceptable, although it does not replace the 
need for the investigator to complete the AE and safety information form  within the 
designated rep orting timelines (as illustrated in the figure below):  
• AE form within 24 hours  
• Safety information form within 5 calendar days  
• Both forms must be signed within [ADDRESS_16954] knowledge by [CONTACT_1275].  
• The specific event form for AEs requiring additional data collection within [ADDRESS_16955] details for SAE reporting can be found in the investigator trial master file.  
 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 69 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  70 of 90 
 
10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information  
Definitions  
Woman of childbearing potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile.   
If fertility is unclear (e.g. amenorrhea in adolescents or athletes), and a menstrual cycle cannot be 
confirmed before first dose of trial treatment, addit ional evaluation should be considered.  
Females in the following categories are not considered WOCBP  
1. Premenarcheal  
2. Females with one or more of the following:  
• Documented total hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
Females with permanent infertility due to an alternate medical cause other than the above (e.g. 
Müllerian agenesis, androgen insensitivity), investigator discretion should be applied in determining 
trial enrolment.  
3. Postmenopausal female:  
• A postmenopausal s tate is defined as amenorrhoea for 12 months without an alternative 
medical cause.  
• Females  ≥ 50 years of age can be considered postmenopausal (irrespective of treatment with 
a hormonal contraception or hormone replacement therapy (HRT)) if they have both:  
o Amenorrhoea and  
o Documentation of 2 high follicle stimulating hormone (FSH) measurements in the 
postmenopausal range and one of these was observed ≥1 year prior to screening.  
• Females ≥ 60 years of age can be considered postmenopausal.  
Females on HRT and whose menopausal status is in doubt are considered of childbearing potential 
and will be required to use one of the highly effective contraception methods.  
Note: Documentation regarding categories 1 -3 can come from the site staff’s review of subject’s 
medical records, medical examination or medical history interview.  
Contraception guidance  
Male subjects   
No contraception measures are required for male subjects as the risk of teratogenicity/fetotoxicity 
caused by [CONTACT_18045].  
Female subjects  
Female subjects of childbearing potential are eligible to participate if they agree to use methods of 
contraception consistently and correctly as described in table below:  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 70 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  71 of 90 
 
Table  10-1 Highly effective contraceptive methods  
CONTRACEPTIVESa ALLOWED DURING THE TRIAL INCLUDE:  
• Highly effective methodsb,d that have low user dependency  (Failure rate of <1% per 
year when used consistently and correctly):  
o Implantable pro gestogen -only hormone contraception associated with inhibition of 
ovulationb 
o Intrauterine device (IUD)  
o Intrauterine hormone -releasing system (IUS)b 
o Bilateral tubal occlusion  
o Vasectomized partner  
(Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential, and the 
absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used. Spermatogenesis cycle is approxi mately 90 days.)  
 
• Highly effective methodsb,d that are user dependent  (Failure rate of <1% per year when 
used consistently and correctly):  
o Combined (estrogen - and progestogen -containing) hormonal contraception 
associated with inhibition of ovulationc 
▪ oral 
▪ intravaginal  
▪ transdermal  
▪ injectable  
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the trial 
treatment. The reliabilit y of sexual abstinence needs to be evaluated in relation to the 
duration of the trial and the preferred and usual lifestyle of the subject.  
NOTES  
a) Contraceptive use by [CONTACT_18046].  
b) Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_17964].  
c) If locally required, in accordance with C linical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.  
d) Contraception should be utilised during the treatment period and for at least 49 days (correspo nding to time 
needed to eliminate trial product) after the last dose of trial product. This period should be extended by 30 days in 
case of genotoxicity.  
 
Pregnancy testing  
• Additional pregnancy testing should be performed during the treatment period, if r equired 
locally ( Appendix 7, Section 10.7). 
• WOCBP should only be included after a negative highly sensitive urine pregnancy test 
(refer to  Appendix 2, Section 10.2). 
• A pregnancy test should be performed at the end of relevant systemic exposure (refer to 
Appendix 2, Section 10.2). 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 71 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  72 of 90 
 
• Pregnancy testing should be performed whenever a menstruation is missed or when 
pregnancy is otherwise suspected.  
Collection of pregnancy information   
Femal e subjects who become pregnant   
• Investigator will collect pregnancy information on any female subject who becomes 
pregnant while participating in this trial.  
• Information will be recorded on the appropriate form and submitted to Novo Nordisk within 
[ADDRESS_16956]'s pregnancy (see Figure  10-2). 
• Subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow -up information on subject and neonate which will be forwarded to Novo 
Nordisk within 14 calendar days. Generally, follow -up will not be required for longer than 1 
month beyond the delivery date.  
• Any termination of pregnancy will be reported, regardless of foetal status (presence or 
absence of anomalies) or indication for procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any adverse event in 
connection with pregnancy or elective termination of a pregnancy for medical reasons will 
be reported as an AE or SAE. If relevant, consider adding ‘gestational’, ‘pregnancy -relate d’ 
or a similar term when reporting the AE/SAE.  
• Pregnancy outcome should be documented in the subject's medical record. Abnormal 
pregnancy outcome (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies 
and ectopic pregnancy) is consider ed an SAE.  
• Any SAE occurring as a result of a post -trial pregnancy which is considered 
possibly/probably related to the IMP by [CONTACT_18047] 10.3. While the investigator is not obligated to actively seek this 
information in former subjects, he or she may learn of an SAE through spontaneous 
reporting.   
Maternal form 1b  
  14 calendar days after birthMaternal form 1a
  14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal form 2   14 calendar days
Paternal form*1   14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 10.1.Prior to 
birth or 
pregnancy 
termination For female subjects
 
Figure  10-[ADDRESS_16957] who becomes pregnant while participating in the trial will discontinue IMP.   
 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 72 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  73 of 90 
 
10.5 Appendix 5: Technical complaints: Definition and procedures for recording, 
evaluation, follow -up and reporting  
10.5.1  Definition of technical complaint  
Technical complaint definition  
• A technical complaint  is any written, electronic or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE but does 
not concern the AE itself.  
Examples of technical complaints:  
• Problems with the physical or chemical appearance of trial products (e.g. discoloratio n, 
particles or contamination)  
• Problems with packaging material including labelling  
• Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen -injector and the needle)  
Time period for detecting technical complaints  
All technical complaints  which occur from the time of receipt of the product at site until the time 
of the last usage of the product must be collected for products predefined on the technical 
complaint form.   
 
10.5.[ADDRESS_16958] be reported on a separate technical complaint form : 
1. One technical complaint form must be completed for each affected DUN.  
2. If DUN is not available, a technical complaint form for each batch, code or lot number must be 
completed.  
 
Timelines for reporting of technical complaints to Novo Nordisk  
The investigator must complete the technical complaint form in the CRF within:  
• 24 hours if related to an SAE  
• [ADDRESS_16959] enter the information on the techn ical complaint form in the 
CRF.  
 
Follow -up of technical complaints  
The investigator is responsible for ensuring that new or updated information will be recorded on 
the originally completed form.  
 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 73 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16960].  
 
10.5.3  Reporting of technical complaints  
Reporting of technical complaints for Novo Nordisk products not included in technical 
complaint form  
Technical complaints on Novo Nordisk pr oducts not included in the technical complaint form 
should be reported to local Novo Nordisk.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 74 90
CONFIDENTIAL
Protoc ol 
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  75 of 90 
 
   
 10.6 Appendix 6: Mitigations to ensure subject safety and data integrity during COVID -[ADDRESS_16961] Novo Nordisk to allow for implementation of mitigations mentioned in this appendix  based 
on mutual agreement.  
• Table  10-2 indicates the minimum requirements for assessments that should be performed 
during a lock -down, but sites should always try to follow the assessments outlined in 
Section 1.2 (original flowchart) to the extent possible. Implementation of specific 
mitigations should be based on assessment of feasibility at the individual site.  
• Sites should comply with local regulati ons, requirements and/or guidelines if they are 
issued.  
10.6.1  Visits  
• Screening (visit 1) and randomisation (visit 2) should always be performed as physical on -
site visits. If a site is unable to perform these visits on -site, screening and randomisation of 
new su bjects at that site should be on hold until on -site visits are possible.  
• Visits 4, 7, 9, 11, 13, and [ADDRESS_16962] 
possible.  
• On-site visits (visits 3, 5, 6, 8, 10, and 12) can be converted to remote visits  (video, phone or 
similar) or home visits.  
• At each visit the investigator must indicate in the eCRF how the visit was performed and 
specify the reason for the preferred assessment method.  
10.6.2  Assessments  
• Assessments used for safety and the confirmatory endpoin ts should be prioritised. The 
preferred order for the method of assessment is: on -site, video, phone, home visit. Findings 
meeting the definition for an AE (refer to Appendix 3  [Section  10.3]) should be reported in 
the eCRF.  
• If the assessments indicated in Table  10-[ADDRESS_16963] possible timepoint following the originally 
scheduled visit in agreement with Novo Nordisk.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 75 90
CONFIDENTIAL
Protocol        Date:  21 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN9536 -4578        Version:  3.0 Page:  76 of 90 
 
   
 10.6.3  Minimum assessments following randomisation to be performed during lockdown  
Table  10-2 Minimum assessments following randomisation to be performed during lockdown  
 Dose escalation period  Treatment period  End of 
treatment  End of trial  
Visit (V)  P3 V4 P5 P6 V7 P8 V9 P10 V11 P12 V13 V14 
Timing  of Visit (Weeks)  4 8 12 16 20 28 36 44 52 60 68 75 
Visit  Window  (Days)  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +[ADDRESS_16964] RELATED INFORMATION AND 
ASSESSMENTS              
Concomitant  Medication  X X X X X X X X X X X X 
Pregnancy  Testc (8.3.5 )  X  X X X X X X X X X 
EFFICACY              
Body  Measurements ( 8.1.2 )             
     Body  Weight   X   X  X  X  X  
Clinical  Outcome  Assessments              
    Western Ontario and McMaster Universities   
Osteoarthritis Index (WOMAC)  (8.1.1 ) X X X X X X X X X X X  
    Patient Global Impression of Status (PGI -S) Pain      X    X  X  
    Patient Global Impression of Change (PGI -C) Pain      X    X  X  
    Short Form 36 V2.0 acute (SF -36) ( 8.1.4 )  X   X  X  X  X  
    PGI-S Physical Function   X   X    X  X  
    PGI-C Physical Function      X    X  X  
SAFETY              
Adverse  Event ( 8.3) X X X X X X X X X X X X 
NN9536-4578 NN9536 0  |  . -  | 2 VV-TMF-4175464
  Protocol  v 3.0  | 76  of 90
CONFIDENTIAL
Protocol        Date:  21 April 2021  Status:  Final  Novo Nordisk  
Trial ID: NN9536 -4578        Version:  3.0 Page:  77 of 90 
 
   
  Dose escalation period  Treatment period  End of 
treatment  End of trial  
Visit (V)  P3 V4 P5 P6 V7 P8 V9 P10 V11 P12 V13 V14 
Timing  of Visit (Weeks)  4 8 12 16 20 28 36 44 52 60 68 75 
Visit  Window  (Days)  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +5  
Technical  Complaint ( 8.3.9 ) X X X X X X X X X X X  
Vital  Signs ( 8.2.3 )             
     Systolic  Blood  Pressure      X  X  X  X X 
     Diastolic  Blood  Pressure      X  X  X  X X 
     Pulse      X  X  X  X X 
Physical  Examination ( 8.2.2 )           X  
TRIAL MATERIAL              
     IWRS  Session   X  X X X X X X X X  
Administration  of Trial  Product ( 6.1)             
     Dispensing  Visit   X   X  X  X    
     Drug  Accountability   X   X  X  X  X  
REMINDERS              
Criteria  for discontinuation ( 7.1)  X X X X X X X X X X   
Diet and physical  activity  counselling ( 6.1.2 ) X X X X X X X X X X X  
Review of the pain and pain medication diaryd (8.1.3 ) X X X X X X X X X X X  
Training  in trial product,  pen-handling  X X X X X        
Hand  out dose reminder  card ( 6.1) X X X X X        
a Demography consists of date of birth, sex, ethnicity, and race (according to local regulation).  
b Smoking is defined as smoking at least one cigarette or equivalent daily.  
c For all female subjects of child -bearing potential.  
d The pain and pain medication diary should be filled in on a daily basis by [CONTACT_18048]9536-4578 NN9536 0  |  . -  | 2 VV-TMF-4175464
  Protocol  v 3.0  | 77  of 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  78 of 90 
 
   
 10.7 Appendix 7: Country -specific requirements   
 
For Denmark:  
Section 5.3 Exclusion criteria no. 27  
Contraceptive measures considered adequate include highly effective contraceptive methods in 
accordance with the CTFG (Clinical Trial Facilitation Group). Such methods include:  
• combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ov ulation (oral, intravaginal or transdermal)  
• progestogen -only hormonal contraception associated with inhibition of ovulation (oral, 
injectable or implantable)  
• intrauterine device (IUD)  
• intrauterine hormone -releasing system (IUS)  
• bilateral tubal occlusion  
• vasectomised partner  
• sexual abstinence  
A combination of male condom with either cap, diaphragm or sponge with spermicide (double 
barrier methods) are not considered highly effective birth control.  
For Canada:  
Appendix 1 Sectio n 10.1.10 Retention of clinical trial documentation  
Part C, Division 5 of the Food and Drug Regulations [C.05.012] requires a 25 years retention period  
For [LOCATION_009]:  
1. Section 1.2 Flowchart  
Ethnic origin and race: Collection not allowed in [LOCATION_009].  
Year of bir th: Only year is collected for the date of birth.  
 
Appendix 1   Section 10.1.13 Indemnity statement  
The French Public Health Code article L 1121 -10 (law n° [ADDRESS_16965] 2004. "The sponsor is respon sible for identification of the harmful 
consequences of the biomedical the research for the person lending himself thereto and for 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 78 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  79 of 90 
 
   
 indemnification of his beneficiaries, except in case of proof, incumbent on it, that the prejudice is 
not attributable to his  fault of the fault of any intervening party, without the sponsor's being entitled 
to call on acts by a third party or the voluntary withdrawal of the person who had initially consented 
to cooperating in the research"  
Section 5.3 Exclusion criteria no. 27  
Contraceptive measures considered adequate include highly effective contraceptive methods in 
accordance with the CTFG (Clinical Trial Facilitation Group). Such methods include:  
• combined (estrogen and progestogen containing) hormonal contraception associat ed with 
inhibition of ovulation (oral, intravaginal or transdermal)  
• progestogen -only hormonal contraception associated with inhibition of ovulation (oral, 
injectable or implantable)  
• intrauterine device (IUD)  
• intrauterine hormone -releasing system (IUS)  
• bilateral tubal occlusion  
• vasectomised partner  
• sexual abstinence  
A combination of male condom with either cap, diaphragm or sponge with spermicide (double 
barrier methods) are not considered highly effective birth control.  
For Norway :  
Section 5.3 Exclusion criteria no. 27  
Contraceptive measures considered adequate include highly effective contraceptive methods in 
accordance with the CTFG (Clinical Trial Facilitation Group). Such methods include:  
• combined (estrogen and progestogen conta ining) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal or transdermal)  
• progestogen -only hormonal contraception associated with inhibition of ovulation (oral, 
injectable or implantable)  
• intrauterine device (IUD)  
• intraute rine hormone -releasing system (IUS)  
• bilateral tubal occlusion  
• vasectomised partner  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 79 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  80 of 90 
 
   
 • sexual abstinence  
A combination of male condom with either cap, diaphragm or sponge with spermicide (double 
barrier methods) are not considered highly effective birth co ntrol.  
For Sweden :  
Section 5.3 Exclusion criteria no. 27  
Contraceptive measures considered adequate include highly effective contraceptive methods in 
accordance with the CTFG (Clinical Trial Facilitation Group). Such methods include:  
• combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal or transdermal)  
• progestogen -only hormonal contraception associated with inhibition of ovulation (oral, 
injectable or implantable)  
• intrauterine d evice (IUD)  
• intrauterine hormone -releasing system (IUS)  
• bilateral tubal occlusion  
• vasectomised partner  
• sexual abstinence  
• A combination of male condom with either cap, diaphragm or sponge with spermicide 
(double barrier methods) are not considered high ly effective birth control.  
 
 
For Spain:  
Appendix 1 Section 10.1.10 Retention of clinical trial documentation  
25 years according to the new Spanish Royal Decree 1090/2015  
Section 5.3 Exclusion criteria no. 27  
Contraceptive measures considered adequate include highly effective contraceptive methods in 
accordance with the CTFG (Clinical Trial Facilitation Group). Such methods include:  
• combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation (oral, intra vaginal or transdermal)  
• progestogen -only hormonal contraception associated with inhibition of ovulation (oral, 
injectable or implantable)  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 80 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  81 of 90 
 
   
 • intrauterine device (IUD)  
• intrauterine hormone -releasing system (IUS)  
• bilateral tubal occlusion  
• vasectomised partn er  
• sexual abstinence  
A combination of male condom with either cap, diaphragm or sponge with spermicide (double 
barrier methods) are not considered highly effective birth control.  
 
For US:  
Appendix 1 Section 10.1.5 Data protection  
In the [LOCATION_002], 21 CFR 312.62(c) and 21 CFR 812.140(d) require 2 years following the date a 
marketing application is approved for the drug for the indication for which it is being investigated; 
or, if no application is to be filed or if the applicati on is not approved for such indication, until 2 
years after the investigation is discontinued and FDA is notified’.   
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 81 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  82 of 90 
 
   
  
10.8 Appendix 8: Abbreviations  
6MWT  six-minute walking test  
ACR  American College of Rheumatology  
AE adverse event  
BMI  body mass index  
CRF  case report form  
CTR  clinical trial report  
DFU  directions for use  
DUN  dispensing unit number  
eCRF  electronic case report form  
FAS full analysis set  
FDA  U.S. Food and Drug Administration  
FDAAA  FDA Amendments Act  
GCP  Good Clinical Practice  
GLP -1 glucose like peptide -1 
HbA1 c glycated haemoglobin  
ICH International Council for Harmonisation  
IB Investigator’s Brochure  
IEC independent ethics committee  
IMP investigational medicinal product  
IRB institutional review board  
IWRS  interactive web response system  
KL Kellgren Lawrence  
MEN2  multiple endocrine neoplasia type [ADDRESS_16966]  
SAE  serious adverse event  
SAP statistical analysis plan  
SF-36 Short Form (36) Health Survey  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 82 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  83 of 90 
 
   
 S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2D Type 2 Diabetes Mellitus  
TMM  trial materials manual  
WOCBP  woman of child bearing potential  
WOMAC  Western Ontario McMasters Osteoarthritis Index  
 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 83 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  84 of 90 
 
 10.9 Appendix 9: Protocol amendment history  
Protocol version 2.0 (23 September 2020)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1 for the 
countries participating in the NN9536 -4578 trial.  
Overall rationale for preparing protocol, version 2.0:  
The rational for preparing protocol version 2.0 is to specify that anti -obesity treatme nt (e.g. 
medication) which is not part of the trial procedures is not allowed. This is to ensure alignment with 
the other clinical trials in the development of semaglutide for weight management and to ensure 
interpretability of treatment effect.   
 
Section # and name  [CONTACT_18059] 6.5 
Concomitant 
medication  The following sentence was added to the 
protocol “ During the trial subjects 
should not initiate any anti -obesity 
treatment (e.g. medication) which is not 
part of the trial  procedures. If such 
treatment is initiated, the subject should 
be instructed to stop the anti -obesity 
treatment .” To not allow for other anti -obesity therapi[INVESTIGATOR_014] 
(medication or bariatric surgery) is crucial to 
control the number of subjects actually on or 
starting other anti -obesity therapi[INVESTIGATOR_17965]. By [CONTACT_18049] -obesity therapi[INVESTIGATOR_17966], it can be expected that only a 
small fraction of subjects will initiate other 
anti-obesity therapi[INVESTIGATOR_014] ( as seen in the phase 3a 
semaglutide trials NN9536 -4373, -4374, -
4375 and -4376), which is considered to be 
sufficiently small to not affect the conclusion 
of semaglutide being superior to placebo in 
subjects with obesity and knee OA.  
 
Section 5.2 Exclusio n 
criteria  The following exclusion criterion was 
added “ Treatment with any medication 
for the indication of obesity within the 
past 90 days before screening”  Obesity medication taken within [ADDRESS_16967] the trial results.  
 
Section 5.2 Exclusion 
criteria  Exclusion criteria 5 has been updated 
from “ Use of pain patches, medical 
marijuana or opi[INVESTIGATOR_2438] ” to “ Use of 
medical marijuana or opi[INVESTIGATOR_2438] ” Pain patches containing NSAIDs are allowed 
in the trial, deleting “pain patches” avoids 
confusion.  
 
Section 8.2 Safety 
assessment  The following concomitant 
illness/medical history was changed to 
the below  
• History of breast neoplasm  
• History of gallbladder disease and 
procedure  
• History of gastrointestinal disorder and 
neoplasm  
• History of musculoskeletal system 
disorder  
• History of pancreatic disease  
• History of psychiatric disorder  
• History of skin cancer and skin d isorder  
• History of weight disorder  Revision and clarification of the specific 
topi[INVESTIGATOR_17967] . 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 84 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  85 of 90 
 
 Other relevant concomitant 
illness/medical history (this also includes 
malignant neoplasm)  
Throughout the 
protocol  Re-introduction of the specification of 
‘pancreatitis’ as ‘acute pancreatitis’  Due to error the ‘acute’ was missing from the 
risk acute pancreatitis. Re -introduction of the 
specification of ‘pancreatitis’ as ‘acute 
pancreatitis’ wa s done to ensure alignment 
with the naming of the Novo Nordisk safety 
committee endorsed risk for semaglutide.  
Section [ADDRESS_16968]’s weight history must be 
recorded in the subject’s medical  record.  To specify that subject’s weight history is 
recorded.  
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 85 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  86 of 90 
 
 11 References  
1. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_16969] of clinical trials on medicinal 
products for human use. 2001.  
2. Kelly T, Yang W, Chen CS, Reynolds  K, He J. Global burden of obesity in 2005 and 
projections to 2030. Int J Obes (Lond). 2008;32(9):1431 -7. 
3. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass 
index among US children and adolescents, 1999 -2010. JAMA. 2012;307(5):483 -90. 
4. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, et al. National, regional, 
and global trends in adult overweight and obesity prevalences. Popul Health Metr. 
2012;10(1):22.  
5. NCD Risk Factor Collaboration. Trends in adult body -mass index in 200 countries from 
1975 to 2014: a pooled analysis of 1698 population -based measurement studies with 19.2 
million participants. Lancet. 2016;387([ZIP_CODE]):[ADDRESS_16970]. J Occup Environ Med. 2010;52(10):971 -6. 
7. Van Nuys K, Globe D, Ng -Mak D, Cheung H, Sullivan J, Goldman D. The association 
between employee obesity and employer costs: evidence from a panel of U.S. employers. 
Am J Health Promot. 2014;28 (5):[ADDRESS_16971] State Medicaid Programs Nearly $8 Billion In 2013. Health Aff (Millwood). 
2015;34(11):1923 -31. 
9. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: 
pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711 -25.e6.  
10. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co -
morbidities related to obesity and overw eight: a systematic review and meta -analysis. BMC 
Public Health. 2009;9:88.  
11. Pi[INVESTIGATOR_17968] T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General 
and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105 -20. 
12. Berghofer A, Pi[INVESTIGATOR_17968] T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity 
prevalence from a European perspective: a systematic review. BMC Public Health. 
2008;8:200.  
13. Masters RK, Reither EN, Powers DA, Yang YC, Burger AE, Link BG. The impact of 
obesity on US mortality levels: the importance of age and cohort factors in population 
estimates. Am J Public Health. 2013;103(10):1895 -901. 
14. Arnold M, Pandeya N, By[CONTACT_18050] G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden 
of cancer attributable to hi gh body -mass index in 2012: a population -based study. Lancet 
Oncol. 2015;16(1):[ADDRESS_16972] BG. Myocardial Infarction and Ischemic Heart Disease in 
Overweight and Obesity With and Without Metabolic Syndrome. JAMA internal medicine. 
2013;174(1):15 -22. 
16. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity 
and type 2 diabetes: what can be unified and what needs to be individualized? J Clin 
Endocrinol Metab. 2011;96(6):1654 -63. 
17. Khaodhiar L, Cummings S , Apovian CM. Treating diabetes and prediabetes by [CONTACT_18051]. Curr Diab Rep. 2009;9(5):348 -54. 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 86 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  87 of 90 
 
 18. Wheaton AG, Perry GS, Chapman DP, Croft JB. Sleep disordered breathing and depression 
among U.S. adults: National Health and Nutrition E xamination Survey, 2005 -2008. Sleep. 
2012;35(4):461 -7. 
19. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, 
Emberson J, et al. Body -mass index and cause -specific mortality in 900 000 adults: 
collaborative analyses of 57 pr ospective studies. Lancet. 2009;373(9669):[ADDRESS_16973] A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden 
associated with overweight and obesity. JAMA. 1999;282(16):[ADDRESS_16974] circumference to nonalcoholic fatty 
liver disease. Gastroenterology. 2006;130(7):2023 -30. 
22. Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of oste oarthritis of the 
knee in older adults: a systematic review and meta -analysis. Osteoarthr Cartil. 
2010;18(1):24 -33. 
23. World Health Organization. WHO Obesity: preventing and managing the global epi[INVESTIGATOR_901]. 
Report on a WHO Consultation on Obesity, Geneva, 3 -5 June, 1997. WHO/NUT/NCD/98.1. 
Technical Report Series Number 894. 2000.  
24. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American 
College of Rheumatology 2012 recommendations for the use of nonpharmacologic and 
pharmacologic  therapi[INVESTIGATOR_17969], hip, and knee. Arthritis Care Res 
(Hoboken). 2012;64(4):465 -74. 
25. Felson DT, Zhang Y. An update on the epi[INVESTIGATOR_17970] a 
view to prevention. Arthritis Rheum. 1998;41(8):1343 -55. 
26. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, 
hypotheses and horizons - a scopi[INVESTIGATOR_17971]. Obes Rev. 2014;15(7):578 -86. 
27. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, et al. Effects of 
intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among 
overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. 
JAMA. 2013;310(12):[ADDRESS_16975] L, Astrup A, C hristensen R. Weight loss as treatment for 
knee osteoarthritis symptoms in obese patients: 1 -year results from a randomised controlled 
trial. Ann Rheum Dis. 2011;70(10):[ADDRESS_16976] of weight maintenance on symptoms of knee osteoarthritis in obese patients: a 
twelve -month randomized controlled trial. Arthritis Care Res (Hoboken). 2015;67(5):[ADDRESS_16977] of Weight Loss on Obstructive Sleep Apnea Among Obese 
Patients With Type 2 Diabetes The Sleep AHEAD Study. Archives of Internal Medicine. 
2009;169(17):1619 -26. 
31. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk 
for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med. 
1992;116(7):535 -9. 
32. Dengo AL, Dennis EA, Orr JS, Marinik EL, Ehrlich E, Davy BM, et al. Arterial destiffening 
with weight loss in overweight and obese middle -aged and older adults. Hypertension. 
2010;55(4):855 -61. 
33. Dattilo AM, Kris -Etherton PM. Effects of weight reduction on blood lipi[INVESTIGATOR_6520]: 
a meta -analysis. Am J Clin Nutr. 1992;56(2):320 -8. 
34. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on 
comorbid conditions. Obes Res. 2001;[ADDRESS_16978] 4:326S -34S. 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 87 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  88 of 90 
 
 35. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. 
American Association of Clinical Endocrinologists' Co mprehensive Diabetes Management 
Algorithm 2013 Consensus Statement - Executive Summary. Endocrine Practice. 
2013;19(3):536 -47. 
36. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest 
weight reduction. Obes Res. 2000;8(3):270 -8. 
37. Deitel M, Stone E, Kassam HA, Wilk EJ, Sutherland DJ. Gynecologic -obstetric changes 
after loss of massive excess weight following bariatric surgery. J Am Coll Nutr. 
1988;7(2):147 -53. 
38. The American Society for Metabolic and Bariatric  Surgery, The Obesity Society, The 
American Society of Bariatric Physicians and the American Association of Clinical 
Endocrinologists. Obesity is a Disease: Leading Obesity Groups Agree (Joint Press 
Release). 19 June 2013.  
39. Mechanick JI, Garber AJ, Hand elsman Y, Garvey WT. American Association of Clinical 
Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 
2012;18(5):[ADDRESS_16979] JC, Frühbeck G. 2014 EASO 
Position Statement o n the Use of Anti -Obesity Drugs. Obes Facts. 2015;8(3):[ADDRESS_16980] E, Yumuk V, Maislos M, Oppert JM, et al. Obesity: the 
gateway to ill health - an EASO position statement on a rising public health, clinical and 
scientific ch allenge in Europe. Obes Facts. 2013;6(2):117 -20. 
42. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. 
Pharmacological management of obesity: an endocrine Society clinical practice guideline. J 
Clin Endocrinol Metab. 2015;100(2) :342-62. 
43. Ferguson C, David S, Divine L, Kahan S, Gallagher C, Gooding M, et al. Obesity Drug 
Outcome Measures. A Consensus Report of Considerations Regarding Pharmacologic 
Intervention [Internet]. 2012 [cited 2018 8 Aug].  
44. Sumithran P, Prendergast L A, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long -
term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597 -
604. 
45. Schwartz A, Doucet E. Relative changes in resting energy expenditure during weight loss: a 
syste matic review. Obes Rev. 2010;11(7):531 -47. 
46. Pasman WJ, Saris WH, Westerterp -Plantenga MS. Predictors of weight maintenance. Obes 
Res. 1999;7(1):43 -50. 
47. Dombrowski SU, Knittle K, Avenell A, Araujo -Soares V, Sniehotta FF. Long term 
maintenance of weigh t loss with non -surgical interventions in obese adults: systematic 
review and meta -analyses of randomised controlled trials. BMJ. 2014;348:g2646.  
48. Gersing AS, Schwaiger BJ, Nevitt MC, Joseph GB, Chanchek N, Guimaraes JB, et al. Is 
Weight Loss Associated  with Less Progression of Changes in Knee Articular Cartilage 
among Obese and Overweight Patients as Assessed with MR Imaging over 48 Months? Data 
from the Osteoarthritis Initiative. Radiology. 2017;284(2):508 -20. 
49. Gudbergsen H, Boesen M, Lohmander LS, Christensen R, Henriksen M, Bartels EM, et al. 
Weight loss is effective for symptomatic relief in obese subjects with knee osteoarthritis 
independently of joint damage severity assessed by [CONTACT_5019] -field MRI and radiography. 
Osteoarthritis Cartilage. 2012;20(6 ):495 -502. 
50. Novo Nordisk A/S. Investigator's Brochure, semaglutide s.c. for weight management and 
non-alcoholic steatohepatitis, projects NN9536 and NN9931 (edition 5). 2019.  
51. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Dis covery of the Once -
Weekly Glucagon -Like Peptide -1 (GLP -1) Analogue Semaglutide. J Med Chem. 
2015;58(18):7370 -80. 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 88 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  89 of 90 
 
 52. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon -like 
peptide -1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. 
Am J Physiol. 1999;276(5 Pt 2):R1541 -4. 
53. Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and 
safety of once -weekly semaglutide monotherapy versus placebo in patients with type 2 
diabetes (SUSTAIN 1): a double -blind, randomised, placebo -controlled, parallel -group, 
multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251 -60. 
54. Aroda VR, Bain SC, Cariou B, Pi[INVESTIGATOR_17972]č M, Rose L, Axelsen M, et al. Efficacy and  safety of 
once -weekly semaglutide versus once -daily insulin glargine as add -on to metformin (with or 
without sulfonylureas) in insulin -naive patients with type 2 diabetes (SUSTAIN 4): a 
randomised, open -label, parallel -group, multicentre, multinational, p hase 3a trial. Lancet 
Diabetes Endocrinol. 2017;5(5):355 -66. 
55. Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and 
safety of once -weekly semaglutide versus once -daily sitagliptin as an add -on to metformin, 
thiazolidinedi ones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56 -week, 
double -blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341 -54. 
56. Ahmann A, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and 
safet y of once -weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 
diabetes (SUSTAIN 3).  European Association for the Study of Diabetes, 52nd meeting 
2016, Oral Presentation #1472016.  
57. Rodbard H, Lingvay I, Reed J, de la Rosa R, Rose L , Sugimoto D, et al. Efficacy and safety 
of semaglutide once -weekly vs placebo as add -on to basal insulin alone  or in combination 
with metformin in subjects with type 2 diabetes (SUSTAIN 5) [abstract]. Diabetologia. 
2016;59(Suppl 1):[ADDRESS_16981] T, et al. Effects of once -
weekly semaglutide on appetite, energy intake, control of eating, food preference and body 
weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242 -51. 
59. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria 
for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the 
knee. Diagnostic and Therapeutic Criteria Committee of the American Rh eumatism 
Association. Arthritis Rheum. 1986;29(8):1039 -49. 
60. European Medicines Agency. Guideline on clinical investigation of medicinal products used 
in the treatment of osteoarthritis (CPMP/EWP/784/97 Rev. 1). 20 Jan 2010.  
61. Banks PA, Bollen TL, Derv enis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis -2012: revision of the Atlanta classification and definitions by 
[CONTACT_5757]. Gut. 2013;62(1):102 -11. 
62. McConnell S, Kolopack P, Davis AM. The Western Ontario  and McMaster Universities 
Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis 
Rheum. 2001;45(5):453 -61. 
63. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of 
WOMAC: a health status inst rument for measuring clinically important patient relevant 
outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J 
Rheumatol. 1988;15(12):1833 -40. 
64. Ware JE, Jr., Sherbourne CD. The MOS 36 -item short -form health surve y (SF -36). I. 
Conceptual framework and item selection. Med Care. 1992;30(6):473 -83. 
65. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. 
ATS statement: guidelines for the six -minute walk test. Am J Respir Crit Care Med. 
2002;166(1):[ADDRESS_16982] US. 1963:1 -8. 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 89 90
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  21 April 2021  Novo Nordisk  
Trial ID: NN9536 -4578  Version:  3.0 
      Status:  Final  
      Page:  [ADDRESS_16983] 
(6MWT) (revised 2015).  
68. Gudb ergsen H, Henriksen M, Wæhrens EE, Overgaard A, Bliddal H, Christensen R, et al. 
Effect of liraglutide on body weight and pain in patients with overweight and knee 
osteoarthritis: protocol for a randomised, double -blind, placebo -controlled, parallel -group,  
single -centre trial. BMJ Open. 2019;9(5):e024065.  
69. Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren -Lawrence 
Classification of Osteoarthritis. Clin Orthop Relat Res. 2016;474(8):1886 -93. 
70. Christensen R, Astrup A, Bliddal H. Weigh t loss: the treatment of choice for knee 
osteoarthritis? A randomized trial. Osteoarthritis Cartilage. 2005;13(1):20 -7. 
71. Clement ND, Bardgett M, Weir D, Holland J, Gerrand C, Deehan DJ. What is the Minimum 
Clinically Important Difference for the WOMAC I ndex After TKA? Clin Orthop Relat Res. 
2018;476(10):2005 -14. 
72. Bellamy. Comparison of transformed analogue and native numeric rating scaled patient 
responses to the WOMAC Index  Internal Medicine Journal  2011;41(Suppl. s1):23.  
73. McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 
2016;26(1):[ADDRESS_16984] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortal eza, Brazil. October 2013.  
75. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2),  Step 4 
version. 09 Nov 2016.  
76. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statemen t from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):[ADDRESS_16985] of 2007 as amended by [CONTACT_18052] "Clinical 
Trials Registration and Results Information Submission". 21 September 2016.  
78. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004.  
79. The European Parliament and the Council of the European Council.  Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on 
medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, a rticle 41. 
Official Journal of the European Communities. [ADDRESS_16986], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
availab le at www.icmje.org.  
 
 
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 90 90
CONFIDENTIAL
Signature [CONTACT_11032]-TMF-4175464 v2.0
Signature [CONTACT_11032]-TMF-4175464 v2.0Reason for signing: Approved Name:
[CONTACT_1221]: ApproverDate of signature: 27-Apr-2021 07:23:59GMT[PHONE_006]
NN9536-4578 NN9536 0  | VV-TMF-4175464  . -  | 2
 |  of   Protocol  v 3.0 91 90

9.1.1 Protocol Attachment
Protocol A ttachment I islocated in the Trial Master File .
If applicable , Protocol A ttachment II is also located in the Trial Master File.
Content: Global key staff and Country  key staff.CONFIDENTIALDate: Novo Nordisk
Version:
Status:Semaglutide s.c. 2.4 mg once weeklyStudy ID: NN9536-4578Clinical Study ReportAppendix 9.1.124 November 2023
1.0
Final
CONFIDENTIAL